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ABSTRACT 
 
The Turos laboratory has been working with N-thiolated β-lactams for years trying to 
understand the mode of action and structural features it needs to have biological activity. 
Over the years new data has shown promising inhibitory activity against various 
microbes. 
In this dissertation, a review of the vast amount of work carried out on N-thiolated β-
lactams in Turos laboratory has been done and their novelty, in terms of structure and 
mechanism has been discussed. A complete outline of our work in the discovery and 
ongoing development of these compounds, starting from our initial, unexpected finding 
of antimicrobial activity for one of the lead compounds, to a more complete 
understanding of their chemical and biological mode of action and potential utility as 
antibacterial compounds, has been provided.  
Previous researches by graduate students in the Turos laboratory have shown that N-
thiolated β-lactams targets Type II Fatty Acid Synthesis (FAS). In process of 
understanding this further, other FAS inhibiting antibiotics like Triclosan were compared 
to our lactams by adding excess of exogenous fatty acids. Results revealed vast 
differences in the MIC value of triclosan and N-thiolated β-lactams, giving an idea that 
there might be a different mode of action or a different target altogether.  
   
xvii 
 
The third chapter discusses the study of attaching hydrophilic C3 side chains like amino 
acids and carbohydrates on N-thiolated β-lactams while studying the influence of 
microbiological activity. From the study it was found that the lengthening of the side 
chain halts the inhibitory activity regardless of whether the side chain contains 
unsaturation or branching. Results showed that polar groups were not well tolerated and 
the inhibitory activity goes down regardless of polarity. 
Finally, research on dual-action antibiotics was discussed. Antibiotics cause continuous 
bacterial resistance and in this aspect use of two drugs with different mode of action can 
call for reduction of the resistance. Herein, N-acyl ciprofloxacin and N-thiolated β-
lactams were connected together via an ester linkage. Six new hybrid compounds have 
been synthesized successfully and tested against E. faecium, K. pneumoniae, A. 
baumannii, P. aeruginosa, and E. cloacae. 
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CHAPTER 1: SYNTHESIS AND BIOLOGY OF N-THIOLATED β-LACTAMS 
 
1.1. Introduction. 
Throughout much of the 20th century, β-lactam antibiotics have been a mainstay as 
therapeutics for treating a wide range of bacterial infections. As a class of organic 
molecules, β-lactams were first reported over 100 years ago from the synthetic 
investigations of Staudinger.
1
 His methodology established a facile procedure for 
preparing the conformationally strained, and at the time, highly unusual, four-membered 
azetidin-2-one (β-lactam) ring from the direct coupling of an acid chloride with an 
appropriate aldimine shown in Figure 1.1.  
 
 
Figure 1.1. Staudinger’s method for synthesizing β-lactams from an acid chloride 
and an aldimine. 
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For many years, this chemistry was largely overlooked, given the scarcity of compounds 
having the β-lactam ring. In 1928, the British microbiologist, Alexander Fleming, 
discovered the antibiotic effects of pencillin, a naturally occurring fungal metabolite 
produced from a Penicillium mold.
2
 Many years later, after much debate over the 
structure of this compound, Dorothy Hodgkin showed by X-ray crystallography that the 
central feature of the penicillin molecule was Staudinger’s β-lactam ring.3 Since that 
discovery, the relevance of the β-lactams  as antibiotics and building blocks for organic 
synthesis has continued to grow, and countless research articles and scholarly reviews 
have already been written on the subject. The number of different classifications of 
bicyclic β-lactam rings has also been expanded considerably, with the most common ones 
being illustrated in Figure 1.2.  
 
Figure 1.2. Common classes of bicyclic β-lactams. 
 
For classical bicyclic β-lactam compounds, antimicrobial activity arises from the ring 
amido nitrogen occupying the site of ring fusion, a feature which enables the nitrogen 
center to be sufficiently pyramidalized to perturb amide planarity and resonance 
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stabilization. In reality, Nature figured out that N-fused bicyclic β-lactams have enhanced 
electrophilicity and reactivity toward nucleophilic ring opening, which makes them 
particularly suitable as antibiotics. Derived biochemically from the coupling of two 
molecules of L-cysteine, penicillin was designed by Nature to mimic the D-alanine-D-
alanine termini of bacterial peptidoglycans, such that it can be recognized readily by 
transpeptidases that interlink peptidic residues between peptidoglycan strands in the 
bacterial cell wall (murein).
3
 An important step observed in bacterial cell wall synthesis is 
the enzymatic cleavage of the D-alanine-D-alanine terminus of the peptidoglycan strand 
and its joining to another peptidoglycan residue within the bacterial cell wall. This crucial 
step is interrupted by penicillin, which irreversibly acylates the catalytic serine within the 
enzyme active site. The consequence of fungi producing penicillin as a secondary 
metabolite is for its defense against bacteria, by chemically weakening the protective cell 
wall of bacterial invaders.  
The first report of N-sulfenylated β-lactams appearing in the literature is that of Shah and 
Cama, in which N-methylthiosubstituted β-lactams were being used to protect the β-
lactam nitrogen center during synthetic operations.
4
 The high reduction potential of the 
nitrogen-sulfur bond make these structures readily cleavable to thiophilic agents, yet 
stable to acids or bases shown in Figure 1.3. 
 
 
 
Figure 1.3. Dethiolation of N-methylthio β-lactams. 
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We became aware of this work when we first began our early studies on N-thiolated β-
lactams in the mid-1990s.
5
 At that time, we had no intentions of exploring 
microbiological or antibiotic applications of these compounds. Instead, we were only 
interested in trying to use the β-lactam ring as a strained ring to influence regioselectivity 
of electrophile-promoted cyclizations of unsaturated sulfides. In the process, an 
electrophile such as molecular iodine or bromine is reacted with the unsaturated substrate 
to generate an electrophile-activated intermediate, which induces the pendant sulfur to 
attack nucleophilically one of the carbon centers of the halonium species (Figure 1.4). 
The result is the formation of either a six-membered ring through a 6-endo ring closure 
process, or a five-membered ring via a 5-exo cyclization. In either case, the cycloadduct 
must undergo subsequent S-dealkylation to afford the isolable bicyclic β-lactam product. 
Our results indicated that it was the five-membered ring that was obtained exclusively.
6, 7
  
 
 
 
Figure 1.4. Comparison of a classical penam ring to three isopenam variants. 
 
The products of these reactions were bicyclic β-lactam rings similar in structure to those 
of the penicillins and cephalosporins. We referred to these ring structures as ‘isopenams’ 
and ‘isocephams’ to draw attention to the fact that the arrangement of the lactam moiety 
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with respect to the sulfur heterocycle is, in effect, isomeric to that of the natural products. 
This is what initially inspired us to consider whether these cyclization adducts could 
possess microbiological properties, and what the stabilities of these or other related 
compounds could be as a consequence of where the lactam functionality lies in the 
bicyclic skeleton. In the late 1990s our laboratory became interested in adapting this 
halocyclization procedure to create new bicyclic β-lactam ring systems in which the 
orientation of the β-lactam unit is translocated to other positions within the framework. In 
considering the penam ring system, for instance, three structural ‘isopenam’ variants can 
be conceived such that the lactam functionality occupies one of three alternative sites 
within the bicyclic framework. These are shown in Figure 1.5.  
 
 
 
Figure 1.5. Comparison of a classical penam ring to three isopenam variants. 
 
Semi-empirical calculations revealed that, of the three isomeric ring structures, the N-S 
fused (‘inversely fused’) bicyclic ring III has about the same thermodynamic stability as 
the classical penam ring found in penicillin, with less pyramidalization at nitrogen and a 
smaller bond angle between the fused rings. Ab initio calculations indicated that the N-S 
fused ring is also somewhat more twisted than the classical penam ring, which reduces its 
LUMO energy level. In addition to these electronic factors, the sulfur moiety can further 
enhance electrophilic character of the lactam carbonyl through electron-withdrawal. 
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We demonstrated that the skeletal core of these interesting N-S-fused bicyclic β-lactams 
could be accessed by using our previously developed halocyclization methodology. This 
is illustrated in Scheme 1.1, where we show the synthetic route to the isopenem rings 4 
and 5 starting from N-methylthio azetidinones 3. The synthesis begins with the 
Staudinger coupling of the N-p-methoxyphenyl imine of phenylpropynal with 
methoxyacetyl chloride. Obtained in the reaction was exclusively the cis-disubstituted β-
lactam 1. The para-methoxyphenyl protecting group of lactam 1 was removed oxidatively 
using aqueous ceric ammonium nitrate. The resulting N-protio β-lactam 2 was then 
treated with n-BuLi at -78
o
C to generate the N-lithio species, which reacted readily with 
methyl methanethiosulfonate to give the desired N-methylthio β-lactam 3. The reaction of 
lactam 3 with iodine in refluxing methylene chloride solution led cleanly and in high 
yield to the bicyclic isopenem 4. The structure of this adduct was confirmed by proton 
NMR spectroscopy as well as by infrared spectroscopy, which showed a distinct C=O 
stretching band near 1790 cm
-1
. This also confirmed the prediction of a strong electron-
withdrawing effect by the N-S linkage on the amide stretching frequency. The 
absorbance can be further moved to ~1800 cm
-
1 by S-oxidation to the sulfonamide 5. We 
noted another interesting detail about the halogenation of lactam 3 to the bicyclic ring, 
specifically, the effect of the β-lactam (electron-withdrawal by the lactam nitrogen) on 
sulfur’s nucleophilicity. The halocyclization of N-acyl sulfenamides 3 requires an 
elevated reaction temperature (40
o
C), indicating that ring closure is not nearly as facile as 
those of closely related sulfides we had studied earlier that occur at temperatures below 
room temperature.  
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Applying this same approach to the corresponding alkenyl systems, we were unable to 
execute the 5-endo halocyclization, and thus could not prepare bicyclo β-lactam 
(isopenam) adduct 10 (Scheme 1.2). Instead, we only obtained the dibromination 
products 9 (in the case of bromination) or the recovered alkene 8 (in the case of 
iodination). Attempts to convert the dibromo adduct 9 to the fused 4, 5-bicyclic ring 10 
likewise were unsuccessful. Thus, we concluded that the geometric constraints of the 
alkenyl or alkyl systems (vs alkynyl) were sufficiently altered to completely preclude 
formation of the isopenam ring. 
 
 
Scheme 1.1. Synthesis of isopenems 4 and 5 by halocyclization. 
 
 
Scheme 1.2. Attempted synthesis of isopenam 10 by halocyclization. 
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In contrast to these highly unfavorable 5-endo cyclization processes, we were able to 
execute the homologous 5-exo ring closures to construct clavulanic acid-type ring 
systems found within structure 15 (Scheme 1.3).  
 
 
Scheme 1.3. Synthesis of isoclavulanate 15 by halocyclization. 
 
Ozonolysis of the alkenyl side chain in alkenyl β-lactam 6 gave aldehyde 11, which 
underwent stereoselective addition of phenylacetylide and subsequent O-acetylation of 
the resulting secondary alcohol to afford propargylic acetates 12. Dearylation of N-aryl 
lactam 12 and subsequent attachment of the N-methylthio substituent provided 14, which 
we then used as a substrate for iodination. In this case, the iodocyclization proceeded 
without incident, and gave bicycle β-lactam (isoclavulanate) adduct 15. Infrared 
spectroscopic analysis indicated once again that the electrophilicity of the β-lactam 
carbonyl in 15 is enhanced, with a stretching frequency of ~1780 cm
-1
. These studies 
revealed that the formation of the 4,5-bicyclic β-lactam fused ring is much more facile 
when it occurs through a 5-exo halocyclization process than via the 5-endo approach. 
Presumably, this reactivity difference arises from stereoelectronic factors governing the 
ring closures. Despite their highly electrophilic nature, all of the N-S fused bicyclic β-
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lactams we prepared by these routes were highly resistant to hydrolysis over a wide pH 
range (pH 1-10). However, they experienced rapid scission of the N-S bonds by reductive 
processes. For instance, attempts to carry out palladium-catalyzed reactions such as Stille 
and carbonylation cross-couplings on the vinyl iodide 15 gave only the ring-opened 
disulfide as a result of PPh3 in the media. None of the bicyclic β-lactam compounds 
showed antibacterial properties against common Gram-positive or Gram-negative 
bacteria. However, to our astonishment, we noted in these in vitro screenings that the 
monocyclic N-methylthio β-lactam precursors 3, 8, and 14 all had strong growth 
inhibitory properties against Staphylococcus aureus, including the deadly strains of 
methicillin-resistant S. aureus, also known commonly as MRSA (Figure 1.6). Thus, we 
decided to delve further into determining whether other monocyclic N-thiolated β-lactam 
variants may also have antibacterial capabilities. 
 
 
Figure 1.6. N-Methylthio β-lactams 3, 8, and 14. 
 
1.2. Studies on monocyclic N-thiolated β-lactams.  
As is the case so often, Nature provides chemists with unusual structures found within 
bioactive molecules. In 1981, two independent groups from the Squibbs and Takeda 
laboratories reported the isolation of the first N-thiolated β-lactams derived from natural 
sources. These β-lactams differed from all previously reported antibiotics by having a 
monocyclic ring with an N-sulfonic acid group attached directly to the nitrogen. They 
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coined these ‘monobactams’ to highlight, for the first time, monocyclic β-lactams are 
indeed known in Nature, and have potent antimicrobial activities (Figure 1.7). 
Aztreonam, the first marketed monobactam, has activity against most aerobic Gram-
negative bacilli including Pseudomonas aeruginosa. These reports confirmed that β-
lactams do not strictly require a conformationally constrained bicyclic ring structure to 
possess antibacterial properties. Moreover, these monobactams display a broad-spectrum 
of activity against aerobic Gram-negative bacteria, but little or no activity against 
Grampositives such as S. aureus, thus broadening the range of microbes that β-lactams 
can act upon. 
 
Figure 1.7. Monobactams and aztreonam. 
 
In the 1980s, Marvin Miller’s laboratory at University of Notre Dame compared the 
bioactivity of the oxamazins, monobactams having an OCH2CO2H group on the lactam 
nitrogen, to the lack of bioactivity of their sulfur analogs, the thiamazins (Figure 1.8).
8
 
Curiously, the oxamazins are potent antimicrobial agents, while the thiamazins are totally 
devoid of antibacterial activity. This remarkable difference in microbiology was 
rationalized as being due simply to the somewhat longer N-S bond of the thiamazins 
compared to the N-O bond of the oxamazins. This slight structural perturbation 
apparently is sufficient to prevent proper alignment of the thiamazin β-lactam ring in the 
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active site of the bacterial transpeptidase. This conclusion is supported by the fact that 
antibacterial activity in β-lactams requires the presence of an ionizable group on or near 
the lactam nitrogen, and within 3.6 Å of the β-lactam carbonyl. Tabtoxinine β-lactam is 
an exception, because it does not act on murein transpeptidases but as a glutamine 
synthetase inhibitor. Given this strict structural requirement for bioactivity, and Miller’s 
published data for the thiamazins, we were intrigued that our N-methylthio lactams 
possess potent antimicrobial activity. Like the thiamazins previously described by Miller, 
N-methylthio lactams 3 and 8 were observed to be stable from pH 1+10 and completely 
impervious toward enzymatic degradation by penicillinases under conditions in which 
penicillin G is rapidly hydrolyzed. From these early studies it became obvious that the N-
methylthio lactams are not functioning in the same manner, or even on the same group of 
bacterial enzymes, as the known β-lactam drugs. 
 
 
Figure 1.8. Oxamazins and thiamazins. 
 
1.3. Structure-activity studies. 
Much of our early efforts to evaluate the microbiological effects of N-methylthio β-
lactams centered on Structure-activity profiling around the four centers of the azetidinone 
ring. Our starting point for these investigations was N-methylthio β-lactam 3. We began 
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simply by varying the lipophilic and steric nature of the ring substituents at the C3 and C4 
centers. One of our first questions was whether bioactivation by an electrophilic species 
in the bacterial cell is required for antibacterial activity of β-lactam 3. As noted in our 
earlier experiments, highly electrophilic reagents such as molecular iodine cause β-lactam 
3 to undergo a 5-endo halocyclization to the isopenem adduct 16 (Scheme 1.4). 
Mechanistically, we postulated this reaction to proceed via the initial formation of an 
electrophile-activated p-complex I, followed by cyclization and formation of a sulfonium 
intermediate II, which should be a powerful alkylating agent. The questions were whether 
this type of process could be occurring in vitro to account for the antimicrobial activity of 
these β-lactams. We viewed this with suspicion, however, given our prior observation 
that the C4-alkenyl and propargylic-substituted analogs 8 and 14 both bore strong 
bioactivity in MRSA, almost equivalent to alkynyl β-lactam 3, even though we had 
shown that lactam 8 could not undergo electrophile-promoted cyclization to its bicyclic 
derivative 10 (Scheme 2) in the manner that the alkynyl variants 3 and 14 do readily. To 
double check this, we prepared two additional alkenyl lactam derivatives, 17 and 18, in 
their geometrically-pure E and Z forms (respectively) for independent testing (Figure 
1.9). Indeed, we again found strong antimicrobial bioactivity for both compounds.
9 
Given their activity, the possibility exists that the electrophile induced cyclization could 
be executed in vitro, in aqueous media, even though the compounds had low propensity 
to undergo this pathway in organic media. 
We therefore wanted to demonstrate this conclusively by replacing the C4 alkene or 
alkyne side chains of these bioactive lactams with a saturated or aryl substituent, which 
we suspected would lead to total loss of antibacterial activity. 
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Scheme 1.4. Electrophile-promoted activation and cyclization of 3. 
 
 
 
Figure 1.9. N-Methylthio β-lactams 11-20. 
 
Upon synthesizing C4-phenylethyl-substituted and C4-phenylsubstituted β-lactams 19 and 
20, we were surprised to find nearly the same level of bioactivity for these two analogs as 
we did for compound 3. This indicated that p-unsaturation within the C4 side chain was 
not a requirement for antibacterial activity, and ruled out the involvement of a cyclization 
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sequence and formation of a putative sulfonium intermediate. We were pleasantly 
surprised that the structurally simple C4 aryl derivative, 20, was about as active as any of 
the other lactams we had tested. As a consequence, we opted to prepare a larger library of 
C4 aryl-substituted lactams to ascertain whether we could further enhance anti-MRSA 
activity by appropriate aryl ring substitution, or identify a potential trend in structure-
bioactivity within this new series. We first looked at analogs 21-29 having various types 
of substituents on the aryl ring (Figure 1.10). In most cases, electron-donating or 
electron-withdrawing groups diminished the activity to some degree, but all were active 
toward MRSA to varying degrees.
10 
The most noticeable improvement in bioactivity occurred when we examined 
halogenated variants 30-41 (Figure 1.11). Screening of these halogenated compounds 
against MRSA indicated that ortho-substituted aryl derivatives displayed the most potent 
activities, regardless of which halogen or the number of halogens was present on the aryl 
ring. The most active of all these C4-substituted analogs is the ortho-chlorophenyl lactam 
30.  
Next, we investigated the effects of the C3 substituent on bioactivity, starting with the 
replacement of the methoxy group of β-lactam 3. A wide variety of new derivatives were 
prepared. We observed that activity of phthalimidyl derivative 42 and the trans-
disubstituted benzylthio derivative 43 was significantly diminished to that of 3, while 
ethyl-substituted β-lactam 44, to our surprise, showed no activity at all (Figure 1.12).  
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Figure 1.10. N-Methylthio β-lactams 21-29. 
 
Similarly, the C3-unsubstituted β-lactams 45 and 46 had only very weak anti-MRSA 
activity, indicating that possibly a somewhat polar C3 group may be required for 
bioactivity rather than a proton or alkyl residue (Figure 1.13). 
We decided to explore this a bit further by structurally modifying our most active 
compound, lactam 30, to create C3-unsubstituted, chloro, iodo, and azido β-lactam 
derivatives 47-50 (Figure 1.14). Of these four, chloro derivative 48 had the strongest 
activity, with zones of inhibition against the MRSA strains being more than double that 
of penicillin and equal to methoxy compound 30.  
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Figure 1.11. N-Methylthio β-lactams 30-41. 
 
 
 
Figure 1.12. N-Methylthio β-lactams 42-44. 
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Figure 1.13. N-Methylthio β-lactams 45 and 46. 
 
The other three lactams were appreciably weaker in bioactivity. Thus, anti-MRSA 
activity follows 30 and 48> 49> 50> 47. We followed this up by examining a selection of 
C3-amino-substituted analogs 51-54, prepared as shown in Scheme 1.5 and described in 
full in the original publication (Figure 1.15). As a consequence of the chemistry, each of 
the compounds was prepared exclusively as the trans diastereomer. 
These C3-amino β-lactams were found to be much less potent against MRSA compared to 
the C3-methoxy compound 30 or to the analogs halo or azido β-lactams previously 
studied. Only N-benzylamine 52 showed moderate in vitro bioactivity. Thus, we 
concluded that secondary and tertiary amino substituents at C3 markedly degrade 
antibacterial activity.  
 
 
Figure 1.14. N-Methylthio β-lactams 47-50. 
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Scheme 1.5. Synthesis of C3-amino-substituted β-lactams 51-54. 
 
 
 
Figure 1.15. N-Methylthio β-lactams 51-54. 
 
Our final series of analogs consisted of different C3-oxygenated derivatives of lactam 30. 
Like for earlier analogs, we aimed to include compounds that contained a broad range of 
electronically and sterically distinct functionalities. For this, C3-alkoxy β-lactams 55-57, 
C3-phenoxy and C3-acetoxy derivatives 58 and 59, and C3-hydroxyl compound 60 were 
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synthesized and compared in vitro (Figure 1.16). While all of these C3-oxygenated β-
lactam analogs showed enhanced anti-MRSA activity compared to penicillin, none were 
as potent as C3-methoxy β-lactam 30, and the slight variations in bioactivity indicate 
subtle differences in lipophilicity, and thus, bacterial membrane permeability. Along with 
these, we had the opportunity to examine several C3-sulfonate analogs 61-63.  
In vitro testing indicated that anti-MRSA activity increases with the lipophilicity of the 
sulfonate moiety: methyl<phenyl<p-tolyl (Figure 1.17). All of the N-thiolated β-lactam 
compounds tested up to this point have either no substituent or are mono-substituted at 
C3. Therefore, we wanted to see if steric crowding around the C3 center could attenuate 
anti-MRSA bioactivity. Several structurally congested tertiary ethers 64-66 and tertiary 
acetate esters 67-70 were prepared and evaluated (Figure 1.18). 
 
 
Figure 1.16. C3-Oxygen-substituted β-lactams 55-60. 
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Figure 1.17. C3-Sulfonated β-lactams 61-63. 
 
These more heavily substituted compounds were made by stereoselective introduction of 
the alkyl or aryl group via Grignard reaction of an α-keto β-lactam as shown and 
described in the publication (Scheme 1.6).
11
 The tertiary alcohol obtained from Grignard 
addition was then O-alkylated or O-acylated, and converted onward to the N-methythio 
derivatives. The nucleophilic attack occurred exclusively from the less hindered a-face of 
the azetidinone ring, to give only one diastereomer in each case. 
 
 
Figure 1.18. C3-Disubstituted β-lactams 64-70. 
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Our data showed that antibacterial activity of these seven derivatives diminished as steric 
crowding on the ring increased. Among the four tertiary ether analogs, the propyl and 
allyl ethers 64 and 65 were more active than the more polar methoxymethyl derivative 
66. Of the acetoxy esters, the methyl and propyl analogs 67 and 69 were at least 33% 
more active than the allyl or phenyl bearing lactams 68 and 70. 
Finally, we also examined spirocyclic lactams 71 and 72, in which the C3 ether is 
contained within a conformationally restricted ring (Figure 1.19). It was found that 
compound 71 was slightly more active than its constitutional isomer 72. We had the 
chance to examine three additional variants, 73-75, which differed from 71 only in the 
pendant C4-phenyl substituent. All had reasonable anti-MRSA activity, but were at least 
25% less active than open-ring (and presumably more sterically congested) analog 65. 
These data point to the irrelevance of the β-lactam ring in governing the microbiology. 
 
 
Scheme 1.6. Synthesis of C3-disubstituted β-lactams 64-70. 
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Figure 1.19. C3-Spiro-substituted β-lactams 71 and 75. 
 
1.4. Effect of relative and absolute stereochemistry on anti-MRSA activity. 
Bioactive molecules tend to be highly dependent on their stereochemistry in terms of 
their target binding or cellular effects. To more clearly ascertain whether this was the 
case for our β-lactams, we prepared the cis and trans stereoisomers of C3-acetoxy N-
methylthio β-lactams 76 and 77 independently, and found that the trans isomer 77 was 
only marginally (about 10%) more active toward MRSA than the cis β-lactam (Figure 
1.20). 
 
 
Figure 1.20. C3-Acetoxy-substituted β-lactams 76 and 77. 
   
23 
 
Simultaneously, the effect of absolute stereochemistry on bioactivity was evaluated in 
more detail, through independent asymmetric synthesis of enantiomeric lactams, (-)-78 
and (+)-78 (Figure 21). This chemistry was developed based on earlier methodology we 
reported for lipase-mediated kinetic resolution of C3-acetoxy β-lactams.  
Both enantiomers of lactam 78 exhibited the same in vitro activity against MRSA, 
showing identical zones of growth inhibition of MRSA on agar plates and minimum 
inhibitory concentration (MIC) values in broth microdilution experiments. Thus, from 
these examinations, we concluded that neither relative nor absolute stereochemistry of 
these lactams really affect antibacterial activity.  
 
 
Figure 1.21. Preparation of enantiomeric β-lactams 78 by enzymatic resolution. 
 
1.5. Effects of the N-organothio substituent on anti-MRSA activity.  
Our ab initio calculations on the N-methylthio β-lactams indicated that the sulfur and 
carbon centers in the N-methylthio group are both electronically neutral. Curiously, the 
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sulfur-carbon bond of the N-methylthio group prefers to be oriented orthogonally relative 
to the lactam ring, with the ‘cis’ rotamer being about 1 kcal/mol more stable than the 
‘trans’. However, the barrier for rotamerization between the cis and trans forms is less 
than 8 kcal/mol, allowing for facile equilibration in solution (which we confirmed by 
variable temperature NMR experiments). The experiments also indicated that this 
energetic difference in cis-trans isomers is enhanced as the size of the alkyl moiety on the 
sulfur center is increased. 
These conformational experiments agreed with those reported by Marvin Miller’s group 
for the thiamazins, but did not explain why the methylthio β-lactams are antibacterially 
active while the closely related thiamazins are not. Our first line of inquiry into 
understanding this was by replacing the N-methylthio moiety of lead β-lactam 3 for other 
types of N-substituents (Figure 1.22). Compounds 79 and 80 were synthetic precursors of 
3 and were thus readily available. Likewise, we prepared N-chloro and N-phenylseleno 
derivatives 81 and 82, respectively, by deprotonation of N-protio precursor 79 with n-
butyllithium at -78 
o
C, and reacting the N-lithiated species with Cl2 or PhSeCl. Although 
the latter two compounds appeared to bleach the cellulose disks during agar diffusion 
experiments, none of these compounds except for N-methylthio β-lactam 3 displayed 
visible zones of growth inhibition indicative of in vitro anti-MRSA activity.
12 
Thus, it appears that the N-thio group is required for antibacterial activity. Next we 
wanted to know if changing the N-methylthio group for different organothio residues 
could enhance anti-MRSA activity, or even help elucidate the process by which these 
compounds act as antibacterials. 
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Figure 1.22. N-Derivatized β-lactams 3 and 79-82. 
 
We investigated this by synthesizing longer chain analogs, 83-86, based on compound 
30, systematically increasing the alkyl chain length (Figure 1.23). It was found that anti-
MRSA bioactivity of these five compounds varied considerably, with N-ethylthio 
derivative 83 being somewhat more active than the N-methylthio (30), but after that, 
activity steadily dropped. In fact, N-octylthio β-lactam 86 retained less than half the anti-
MRSA activity of 30. We considered the possibility that antibacterial activity of these 
chain elongated N-alkylthio β-lactams diminishes because of an artifact in testing on agar 
plates, such that chain elongation leads to decreasing ability of the lipophilic β-lactam to 
diffuse through the agar, producing smaller zone sizes. 
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Figure 1.23. N-Alkylthiolated β-lactams 30 and 83-86. 
 
However, testing each of the compounds in broth by measuring the minimum inhibitory 
concentrations showed, indeed, that this trend in diminishing bioactivity with increasing 
alkyl chain length was real. Kirby-Bauer growth inhibition zone sizes correlate with MIC 
values, and thus either method afforded a reliable way to gauge bioactivity within a 
closely related series of analogs using 20 mg of test compound. 
Investigations were subsequently carried out to determine if chain branching within the 
N-alkylthio moiety, as a means to maximize lipophilicity of the thio moiety without 
causing chain elongation, could enhance antibacterial activity. For this, we prepared N-
organothio-substituted β-lactams 87-92, which were then evaluated for anti-MRSA 
activity (Figure 1.24). 
N-Isopropylthio and sec-butylthio analogs, 87 and 88, showed increased bioactivity 
against MRSA compared to the N-methylthio or N-ethylthio β-lactams (30 and 83). 
However, the N-cyclohexylthio, N-phenylthio, and N-benzylthio β-lactams 90-92 were 
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less effective than 87 or 88. Of all the compounds tested, N-sec-butylthio β-lactam 88 
possesses the strongest bioactivity against MRSA. 
 
 
Figure 1.24. N-Thiolated β-lactams 87-92. 
 
All of the analogs thus far found to have antibacterial properties have been N-
sulfenylated derivatives. The next question we asked was whether the corresponding N-
sulfinyl or N-sulfonyl analogs could likewise be bioactive. We addressed this by 
preparing N-sulfinyl β-lactam 93 and N-sulfonyl analog 94 by treating N-cyclohexylthio 
precursor 90 with 30% hydrogen peroxide in glacial acetic acid (Scheme 1.7). The N-
sulfinyl product 93 was prepared as a 1:1 diastereomeric mixture, and adding excess 
amounts of hydrogen peroxide to this mixture gave the N-sulfonyl product 94. Upon 
testing, we observed that the N-sulfenyl and N-sulfinyl β-lactams each showed 
bioactivity, while N-sulfonyl analog 94 was inactive. Thus, it seems from this that either 
the N-sulfenyl or N-sulfinyl β-lactams can be used equivalently at least for MRSA. 
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Scheme 1.7. Synthesis of N-sulfinyl and N-sulfonyl β-lactams 93 and 94. 
 
Continuing this to the more highly S-oxidized variants, N-sulfonate salt 95, and N-
sulfonic acid 96 were synthesized from the N-protio precursor and each was found to be 
completely inactive against MRSA (Scheme 1.8). 
 
 
Scheme 1.8. Synthesis of N-sulfonated β-lactams 95 and 96. 
 
1.6. Effect of ring chirality in the alkylthio chain on anti-MRSA activity. 
Earlier, we illustrated that relative and absolute stereochemistry of the azetidinone ring 
did not appear to play any role in determining the antibacterial activities of the N-
methylthio β-lactams. We did note that trans-disubstituted analogs seemed to be slightly 
more active than the cis isomers, as for compounds 76 and 77. We also showed that the 
(+) and (-) enantiomers of the 3-acetoxy β-lactam 78 had identical anti-MRSA 
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bioactivity. With the discovery that the N-sec-butylthio substituent endowed the β-lactam 
ring with optimal anti-MRSA bioactivity, surpassing even that of the N-methylthio or N-
ethylthio-substituted analogs, we recognized that the N-sec-butylthio analog 88 was 
tested as a mixture of enantiomeric diastereomers 97, 98, ent-97, and ent-98 (Figure 
1.25). We then took it upon ourselves to develop a stereospecific synthesis of each of the 
four isomers, for independent testing, to see if they had the same bioactivity or not. We 
achieved this with diastereoisomeric N-sec-butylthio lactams, 97 and 98, along with their 
enantiomeric forms. 
It was surprising to find that diastereomeric β-lactams 97 and 98 had the same anti-
MRSA activities, as did their enantiomeric counterparts ent-97 and ent-98 to each other, 
but ent-97 and ent-98 were 10-15% more active than 97 and 98. 
 
Figure 1.25. Chiral N-sec-butylthio β-lactams 97, 98, ent-97, and ent-98. 
 
While the differences in bioactivity were certainly not all that significant, they were 
discernible. What is curious is that the absolute stereochemistry of the β-lactam ring itself 
has an effect on bioactivity only when the N-organothio group is also chiral (N-sec-
butylthio), but not when the N-moiety is achiral (N-methylthio). Overall, this preliminary 
data identified some general trends in the structural requirements of the C3 and C4 ring 
substituents of N-alkylthio β-lactams. There seems to be a need to balance the lipophilic 
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character of the C3 and C4 groups to obtain an optimal anti-MRSA activity, with C3-
alkoxy or acyloxy side chains and C4 aryl moieties affording the best bioactivity 
combination. This structure-activity profile maps better to the compound’s ability to 
penetrate the bacterial cell membrane to sites of action within the cytoplasm than to any 
specific non-bonding interactions with a biological target such as an enzyme or vital 
biomolecule. Polar substituents on the azetidinone ring presumably make it harder for the 
compound to penetrate through the membrane and would thus be expected to diminish 
antibacterial activity, while those compounds having too much lipophilicity are likely to 
be sequestered in the membrane or internal organelles, lowering the effective 
concentration in the cytoplasm. 
 
1.7. Probing the antibacterial activity of N-thiolated β-lactams.   
Until this point, all of our studies of N-thiolated β-lactams have focused on their 
structure- activity toward Staphylococcus bacteria. What we learned from this work, so 
far, is that the ring functionality did have a role, albeit still a rather undefined one, on the 
in vitro anti-MRSA properties of the β-lactams. Most significantly, the N-organothio 
moiety is an absolute requirement for bioactivity. To extend these investigations further, 
we set out to evaluate what other microbes these compounds could act upon. Our 
laboratory conducted a survey to test for in vitro activity toward a much wider range of 
Gram-positive and Gram-negative microbes, listed alphabetically in Table 1.1. For most 
of the 23 genera tested, more than one species or strain was evaluated, as indicated in 
parentheses. The table summarizes the relative susceptibilities of each genera to a 
selection of different β-lactams, as determined by Kirby-Bauer agar diffusion assays. 
   
31 
 
Those microbes demonstrating high susceptibility to the β-lactams showed large growth 
inhibition zones, denoted with an X while others giving no zones are identified as being 
insensitive to the compounds. Although bioactivity varied considerably among the β-
lactam derivatives, the data were pretty consistent in terms of which microbes were 
susceptible. We noted immediately that while most of the bacteria tested were not 
affected by the β-lactams, a few important pathogenic species such as Staphylococcus, 
Micrococcus, and Bacillus were. Additionally, moderate levels of activity were found 
against Bacteroides, Streptococcus, Neisseria gonorrhoeae, while weaker activity was 
found against Salmonella typhimurium, Vibrio cholerae, and Mycobacterium 
tuberculosis. 
None of the lactams were active toward Enterobactor cloacae, Escherichia coli, 
Klebsiella pneumoniae, Listeria monocytogenes, Bacteroides fragalis, Serratia 
marcessens,   P.  aeruginosa,   or  Proteus   mirabilis.  Thus,   the   selection of microbes 
affected by the β-lactams is extremely narrow; nine genera in total from the microbes 
studied, and not related to whether the microbe is Gram-positive or Gram-negative. This 
is highly unusual for any family or class of antibacterial agents, and certainly, not at all 
characteristic of the β-lactam antibiotics. The most highly susceptible bacteria were those 
from four distinct taxonomic orders as deﬁned by their genetic, morphological, and 
metabolic traits, although few  taxonomic relationships could be found  to account for the 
unusual   spectrum  of   antimicrobial  activity.
13
   We   could  ascertain, however, that the 
class  most affected by the N-thiolated β-lactams  was  the ‘Bacilli’, which consists of 
two orders: Bacillales and Lactobacillales, with Bacillus, Staphylococcus, and 
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Streptococcus being the most  susceptible  members. Other ‘Bacilli’, such as 
Enterococcus, Lactococcus, and Listeria, were largely insensitive to the lactams. 
In screening against staphylococci, broad bioactivity was found for most of the β-lactams  
against various species of Staphylococcus, not only  S. aureus  (MSSA and MRSA), but 
also  Staphylococcus epidermidis, and Staphylococcus lugdunensis; however, we  noted 
that Staphylococcus lentus and Staphylococcus simulans were somewhat less reliable in 
their susceptibility, with some β-lactams  showing no in vitro bioactivity on agar plates. 
Given  that  Staphylococcus and Bacillus are both in the Bacillales taxonomic order of 
bacteria, we  examined the β-lactams  for  bioactivity against seven species of bacilli, 
including Bacillus anthracis, Bacillus  globigii,  Bacillus  thuringensis,  Bacillus 
megaterium, Bacillus coagulans, Bacillus subtilis, and Bacillus cereus.  
The most prominent of these seven, B. anthracis is a rod-shaped Gram-positive bacterium 
that causes anthrax infections.   
If inhaled, spores of B. anthracis rapidly migrate to lymphonodes of the lungs, where 
they begin to germinate and release toxins that cripple the immune response, causing 
bacteremia, toxemia, and frequently, death. Thus, the fact that these lactams show 
promising in vitro activity against B. anthracis is signiﬁcant. Structure-activity mapping 
showed that, in general, lipophilic acyloxy  or  alkoxy groups at  C3   of  the  β-lactam 
ring  lead to the strongest growth inhibition properties  against the seven Bacillus  species  
examined,  suggesting that Bacillus  may be more sensitive  than  Staphylococcus to  
lipophilicity within  the C3- alkoxy side  chain. The propoxy and allyloxy side chains 
were also slightly more active than the parent C3-methoxy derivative. Spirocyclic ethers 
at C3 were less active than the open chain variants. 
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Table 1.1. Susceptibility comparison of N-methylthio β-lactams 67-81, 83, and 97-99. 
Bacteria     Zone of Growth Inhibition  (mm)   
susceptibilities         high  moderate weak none 
(Species:Strains) Gram (±) >30 21-30 15-20 <15  0 
Bacteriodes sp. (1:1) -   X X X 
Bacillus spp. (7:7) +  X X X  
Enterobacter sp. (1:1) -     X 
Enterococcus spp. (6:6) +    X X 
Escherichia sp. (1:3) -     X 
Fusobacterium spp. (6:16) -     X 
Haemophilus sp. (1:3) -    X  
Klebsiella sp. (1:1) -     X 
Lactococcus sp. (1:1) +    X X 
Listeria sp. (1:2) +    X X 
Micrococcus sp. (1:1) + X X    
Mycobacterium sp. (1:1) -     X 
Neisserria sp. (1:2) -   X X X 
PeptoStreptococcus sp. (1:1) +     X 
Porphyromonsa (1:2) -     X 
Proteus sp. (1:1) -     X 
Pseudomonas sp. (1:1) -     X 
Salmonella sp. (1:1) -    X X 
Serratia sp. (1:1) -     X 
Sporobolomyces sp. (1:1) -     X 
Staphylococcus spp. (10:21) + X X X X X 
Streptococcus spp. (2:2) +   X X X 
Vibrio sp. (1:2) -    X X 
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The most important determinant of anti-Bacillus activity, as in the case for MRSA, was 
found to be the N-organothio moiety, with the sec-butylthio compound 88 having the best 
overall bioactivity. Examination of 88 against the seven Bacillus bacteria likewise 
determined that this compound was signiﬁcantly more active than N-methylthio β-lactam 
30, with zone sizes being more than double than those produced by the N-methylthio β-
lactam 3, and equivalent to that of ciproﬂoxacin. The MIC values for lactam 4 against 
both the avirulent Sterne and virulent Ames strains of B. anthracis were 0.5 mg/ml.
14
 As 
for Staphylococcus, anti-Bacillus activity requires the N-sulfenyl side chain, since the 
more highly oxidized N- sulﬁnyl, N-sulfonyl, and N-sulfonate derivatives were all 
ineffective. These structure-activity patterns were very similar to those observed for 
MRSA, suggesting that the mode of action of these lactams in Bacillus (and probably 
other susceptible bacteria) is the same as in Staphylococcus. 
 
1.8. Studies to determine the mode of action of N-thiolated β-lactams as  
antibacterials. 
The unusual selectivities and structure-activity trends of these compounds suggest a 
unique mode of action in bacteria. The ﬁrst thing we wanted to ﬁgure out was whether 
these β-lactams function as bacteriostatic or bactericidal agents. To do  this,  we 
examined the effects of  β-lactam  3  on  cell  growth  by measuring cell survival for  
methicillin-susceptible  S. aureus  (MSSA)  and MRSA, respectively, in  the absence or  
presence of β-lactam 3  over a 2 h time frame.  In the absence of β-lactam 3, MSSA and 
MRSA grew logarithmically as expected, but in the presence of β-lactam 3, bacterial 
growth was immediately stopped. While we observed bacteria growth to be inhibited by 
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β-lactam 3, there was little if any decrease in the number of viable cells at or above the 
MIC of the β-lactam. This is indicative of a bacteriostatic effect. The surprising ﬁnding 
that these N-thiolated β-lactams are bacteriostatic agents and act on only a narrow range 
of seemingly unrelated bacteria suggested to us that their mode of action, and even 
perhaps their biological target, is likely internalized within the bacterial cell. Preliminary 
insight on the cellular target(s) of a new antibiotic can sometimes be extrapolated from 
those of other known antibacterial   drugs.  For  instance,   those   that   act   on   major  
intracellular processes such as protein synthesis (chloramphenicol) or production of  
secondary  metabolites  (sulfa drugs) are   generally bacteriostatic agents, while those that 
affect the outer periphery of cells  such as the bacterial membrane (polymyxins, 
bacitracin, cationic  lipoproteins), the cell  wall  (penicillin, vancomycin) or  DNA 
(metronidazole) are largely bactericidal. Thus, we tried to ﬁrst come up with a possible 
mechanism of action for these β-lactams, by identifying the chemical pathway by which 
the lactams exert their microbiological effects, and whether any primary cellular process 
(protein, nucleic acid, or fatty acid biosynthesis) may be altered. 
Although structure-activity proﬁling of bioactive compounds has historically been a 
necessary and valuable component to maximizing efﬁcacy or stability, it is not typically 
very informative in understanding the compound’s mechanism of action particularly in 
the absence of compelling structure-bioactivity trends. Nevertheless, we did learn some 
valuable information from the prior studies outlined above. First,  we  conﬁrmed that the 
N-organothio substituent was a mandatory requirement for bioactivity, not the β-lactam 
ring  or its other ring  substituents, and this allowed  us to rule out a variety of other 
mechanisms including nucleophilic opening of  the β-lactam ring.   Conﬁrmatory proof of 
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this came from the isolation of the N-protio lactam from the culture media treated with 
N-thiolated β-lactam, and the subsequent observation that this substance possesses no 
inherent bioactivity of its own even after prolonged exposure to the microbes in culture. 
We also found that lipophilic ring substituents at C3 and C4 seemed preferable, such that 
polar moieties decrease, not enhance, bioactivity. This again indicates that the 
compounds most likely must traverse the bacterial membrane to get to their target, which 
is not the usual membrane-bound transpeptidase that other β-lactams act upon selectively. 
Thus, compounds having side chains that differ slightly in their bulk or lipophilicity had 
somewhat different levels of antibacterial activities. This relates better to membrane 
permeability properties than to any direct interaction of the molecule with a speciﬁc 
cellular protein or active site functionality. 
 
 
1.8.1. Radioisotope studies. 
To begin to examine the cellular processes affected by the β-lactams, we carried out some 
classical radio-uptake experiments using β-lactam 3 as the model antibiotic. Typically, 
drugs that act on transcription or translation are bacteriostatic, suggesting that N-thiolated 
β-lactams could also inhibit protein synthesis. We looked at this by following the 
incorporation of radiolabeled 
3
H-uridine into RNA, by culturing S. aureus with varying 
concentrations of β-lactam 3 versus rifampicin, a potent RNA synthesis inhibitor. β-
lactam 3 modulated 
3
H-uridine incorporation, though not anywhere close to the extent or 
immediacy  of  rifampicin, suggesting that  transcription  cannot be  the primary process 
targeted by the β-lactams. To further substantiate that N-thiolated β-lactams do not alter 
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nucleotide assimilation into double-stranded DNA (DNA synthesis), pulse-labeling 
experiments were run with 
3
H-thymidine to monitor DNA replication in living bacteria, 
in the presence or absence of β-lactam 3 and suitable controls.  While the control 
antibiotic ciproﬂoxacin inhibited thymidine uptake, both lactam 3 and penicillin G did 
not. To determine if β-lactam 3 could instead directly inhibit protein transcription in 
bacteria, we monitored the rate of uptake of 
3
H-isoleucine in a culture of S. aureus treated 
with either β-lactam 3 or chloramphenicol (a translation inhibitor). These studies 
indicated that the lactams have a measurable, but delayed, response on protein synthesis 
in S. aureus, and certainly this also could not be the primary cause of antimicrobial 
activity of these β-lactams. 
The effect of the lactams on fatty acid biosynthesis in S. aureus was then considered. In 
this case, we saw an immediate and dramatic effect on the rate of uptake of 
3
H-acetate 
from the media when S. aureus cells were treated with β-lactam 3. The blockage of 
radioisotope incorporation into the cell in the presence of the N-methylthio β-lactam, but 
not penicillin or DMSO controls, indicated that the inhibition of fatty acid biosynthesis is 
a primary mode of action in S. aureus. 
 
1.8.2. Microscopy studies. 
It is well-documented that bacteria that are exposed to cell wall inhibitors (i.e., classical 
β-lactams) or to antibiotic agents that act on the cytoplasmic membrane (i.e., polymyxins) 
induce severe cellular damage easily observable by scanning electron microscopy (SEM). 
Therefore, to try to ﬁnd such alterations in bacteria treated with our N-thiolated β-
lactams, we inoculated cultures of S. aureus with β-lactam 3, and examined those cells by 
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SEM for visual damage. The samples were prepared from Kirby-Bauer agar diffusion 
plates by cutting out regions of the agar along the outermost edges of the growth 
inhibition zones, where antibiotic concentrations were insufﬁcient to completely   stunt 
bacterial growth. S. aureus cells that had no exposure to any antibiotic or those surviving 
treatment with β-lactam 3 both displayed identical, grape-like clusters of uniformly 
formed, spherically-shaped cells. This provided additional evidence that N-thiolated β-
lactams do not inhibit bacterial cell wall biosynthesis, or alter the integrity   of   the   
cytoplasmic membrane. Conversely, S. aureus surviving treatment with penicillin G was 
severely damaged and morphologically deformed, as a result of penicillin’s effects on 
cell wall   biosynthesis.  As  expected, the untreated  and  β-lactam  3 treated S. aureus  
cells  retained the purple coloration upon Gram-staining indicative  of   a   fully   intact,   
resilient cell wall, while penicillin-treated S. aureus cells  took on  a  light pink coloration 
characteristic of a highly damaged, morphologically altered cell wall. This further 
indicated that the N-thiolated β-lactam 3 does not affect bacterial cell morphology or the 
integrity of the cell wall in the manner that murein transpeptidase inhibitors like 
penicillin (or other β-lactams) act. 
Unlike the bactericidal damage done by penicillin, which selectively inhibits the ﬁnal 
cross-linking step in bacterial cellwall biosynthesis, N-thiolated β-lactams are 
bacteriostatic toward a very select range of pathogenic bacteria, and do not block 
bacterial cell wall constitution or overall cell morphology.  In  contrast to the dependency 
of the  lactam’s  bioactivity on  the N-thio moiety,  the broad tolerance of substituents at 
the other two ring positions (or on  the lactam ring  itself) suggests that these groups may 
not play a direct role in the binding or reactivity of the drug with a biological target, but  
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more likely,  may inﬂuence bacterial cell  uptake  and membrane  permeability.   Further, 
it was recently shown that structurally related N-alkylthio-2-oxazolidinones closely 
mirror these same trends, demonstrating that the four-membered β-lactam ring itself is 
not even  essential for bioactivity.
15
 
To begin probing  the  chemical  means  by  which  these  N-thiolated β-lactams  operate, 
three basic reaction pathways were considered in  which a biological nucleophile  could 
attack: (1) acylation with β-lactam ring opening, (2)  alkylation, or (3)  sulfenylation  
(Scheme  1.9).   The differences  between   these  three possibilities are that  a  biological  
nucleophile (Nu-) attacks the carbonyl carbon of  the β-lactam ring resulting  in  ring  
opening (acylation), the alkyl  carbon to form  a Nu-alkyl   derivative (alkylation) or  the 
sulfur center resulting in loss of the organothio side  chain (sulfenylation). 
For the ﬁrst pathway depicted, acylation by the β-lactam is the common pathway used by 
the penicillins and cephalosporins, enabling the formation of a hydrolytically stable acyl 
serine ester as a means to irreversibly inhibit murein transpeptidases.
16
 For β-lactam 
antibiotics, it is often just assumed that the azetidinone ring undergoes nucleophilic 
addition at the carbonyl center, followed by opening of the strained four-membered ring.   
It has been well-established that for penicillins and cephalosporins, this acylation 
mechanism requires recognition by the penicillin-binding proteins, murein 
transpeptidases that attack the azetidinone ring nucleophilically with an active site serine 
to create an acyl ester linkage. The acylation process is enhanced by ring strain and the 
positioning of a critical carboxylic acid functional group in proximity to the carbonyl of 
the β-lactam. The lack of an acidic functionality on the framework of the N-thiolated β-
lactam suggests that binding and subsequent ring opening by this acylation mechanism 
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would be extremely unlikely, given the stability of these compounds toward acid or base 
hydrolysis or to ring cleavage by β-lactamases. Moreover, our experiments showed that 
N-thiolated β-lactams do not serve as β-lactamase inhibitors, and thus have no ability to 
impede enzymatic hydrolysis of penicillin G. Most signiﬁcantly, for our C3-disubstituted 
analogs steric crowding around the carbonyl center would work to block nucleophilic 
attack.  We showed this pathway not to be viable. 
Next, we considered the second mechanistic possibility depicted, that the compounds 
could serve as alkylating agents toward cellular nucleophiles. We felt from the start that 
our structure-activity studies did not support this pathway, since nucleophilic attack on 
the alkylthio carbon center should be deterred by bulkier, branched alkyl moieties. 
Experimentally, we found just the opposite outcome, with the N-ethylthio, N-
isopropylthio, and N-sec-butylthio lactams (83, 87, and 88, respectively) being 
increasingly more active than the N-methylthio derivative 30. We also corroborated this 
by evaluating the ability of β-lactam 3 to serve as a DNA alkylating agent in vitro, where 
transfer of the methyl from the N-methylthio β-lactam 3 onto the nucleic acid should 
inhibit DNA replication or compromise the integrity of the helices. Examples of DNA 
alkylating agents that exhibit such antibacterial properties include leinamycin and 
mitomycin, which are cidal in their activity. The N-methylthio lactam compounds, 
however, are bacteriostatic and thus unlikely to function as DNA alkylators. However, 
we ran some experiments to conﬁrm this. 
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Scheme 1.9.  Three alternative reaction pathways for N-thiolated β-lactams . 
 
First, we carried out studies to determine if N-thiolated β-lactam 3 could directly cause 
strand breakage of supercoiled DNA. We treated the plasmid pBR322  at varying 
concentrations of β-lactam 3 (5-100 mM) in sodium phosphate buffer for 24 h, and 
double strand (fragmentation) and single strand (linearization)  breakages were then 
analyzed by agarose gel electrophoresis containing 1% ethidium bromide. It was 
immediately evident that at these high concentrations the β-lactam failed to induce 
fragmentation or relaxation of the plasmid superhelix by chemical modiﬁcation of the 
DNA. Given that some DNA alkylators require chemical activation, often by a thiol-
mediated reaction in thiol-rich intracellular environments, we also showed that β-lactam 3 
in the presence of glutathione, dithiothreitol, or β-mercaptoethanol also had no effect on 
the plasmid. Thus, these β-lactams do not appear to be capable of alkylating bacterial 
components to any extent that could account for their microbiological properties. 
Finally, we consider the third pathway, sulfenylation by transfer of the N-organothio 
moiety from the β-lactam onto a cellular thiol. This pathway was supported by the ﬁnding 
that when we treated a culture of S. aureus with N-alkylthio β-lactam 30, N-protio β-
lactam was isolated cleanly by extraction of the media with ethyl acetate (Figure 1.26). 
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This shows the facility in which the β-lactam transfers the N-organothio entity to a 
bacterial thiophile. 
 
Figure 1.26. N-Methylthio β-lactam 30 undergoes N-dethiolation upon exposure to 
S. aureus. 
 
Among the more ubiquitous  organothiols in bacteria  are those forming the native redox 
buffer in  cells,  whose role is to preserve proteins in their  correct oxidation state and to  
remove damaging  pollutants such  as  extraneous  oxidants and  alkylating  agents.  The 
most common of these is glutathione, a tripeptide that is found in high concentrations in 
the cytoplasm of most bacteria and in human cells (Figure 1.27). 
 
Figure 1.27. Structure of glutathione. 
 
To further illustrate the sensitivity to glutathione, we re-ran the Kirby-Bauer well 
diffusion experiments, but this time β-lactam 30 was co-mixed with glutathione before 
being added to the diffusion well.  Varying the β-lactam/glutathione ratio in  the wells  
veriﬁed that the biological activity of these β-lactams  against S. aureus  was reduced  as   
the  amount  of   glutathione  in the  mixture  was incrementally  increased.  Additionally, 
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a  simple  Kirby-Bauer  well diffusion experiment was carried  out  to determine if 
glutathione could   alter   the    anti-staphylococcal   properties   of   different N-alkylthio 
β-lactam derivatives, in this case, N-methylthio β-lactam 30, N-ethylthio β-lactam 83, 
and N-sec-butylthio β-lactam 88 (Figure  1.28).  For this, an agar plate was prepared such 
that 1 mg  of glutathione was added (as an aqueous solution) into a small (6 mm wide) 
well  cut  into the agar at  the  center of the plate. The three β-lactam derivatives were 
then added (dissolved in DMSO) to individual wells on the outer perimeter of the plate, 
equidistant from the center well.  The plate was then incubated for 24 h. The shape of the 
resulting growth inhibition zones appearing around the wells of the three β-lactams was 
all noticeably ‘indented’ on the side facing the central well.  This indicated that the 
outward diffusion of the glutathione from the center well negated the growth inhibitory 
effects of the β-lactams on the microbe, in all three cases.  
 
 
Figure 1.28. N-Methylthio β-lactam 30, N-ethylthio β-lactam 83, and N-sec-butylthio 
β-lactam 88. 
 
We then ran an experiment to show that these same three N-alkylthio lactam derivatives 
possess different sensitivities to glutathione under bacterial growth conditions, by varying 
the amounts of glutathione added to the growth media. As shown in Figure 1.29, N-
   
44 
 
ethylthio lactam 83 and N-sec-butylthio lactam 88 both possessed their full antibacterial 
activity against S. aureus  in the presence of  a  small amount (20 mg)  of  glutathione  
(left plate, A), while N-methylthio  lactam  30  was  completely inactivated.  Thus, of the 
three, the N-methylthio derivative was rapidly neutralized by the glutathione.  Increasing  
the  amount of glutathione in the agar  (50 mg,  right plate, B) showed that now both  the  
N-methylthio  and the N-ethylthio β-lactams   completely  lost   their  bioactivity,  while  
the  N-sec-butylthio compound   was  still   strongly  active.  Thus,   the three   N-alkythio 
lactams do   not   have   the same   stabilities   to glutathione (or possibly other cellular 
thiophiles), with the order of stability being N-methylthio<N-ethylthio<N-sec-butylthio.   
This difference in glutathione stabilities (at least when determined in the presence of S. 
aureus) matches identically to the observed antibacterial activities of the three β-lactams 
toward S. aureus (including MRSA). Although  this similarity  in trends is still  difﬁcult  
to  completely rationalize, we  had   the ﬁrst insight that microbiological  activities of  the  
N-thiolated β-lactams can be highly dependent on differences upon reaction with  
thiophilic nucleophiles in  the bacterial cell. 
These experiments showed that high levels of glutathione, such as that found naturally in 
the cytoplasm of most microbial cells as well as human tissue, serve a protective role in 
obviating the cellular effects of these N-thiolated β-lactams. We felt this could possibly 
explain the differences in bioactivity these compounds have toward other microbes that 
we examined in our in vitro assays. For instance, E. coli and P. aeruginosa are two of the 
bacteria that showed no susceptibility to these drugs, and both are reported to have high 
cytosolic levels of glutathione. 
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Figure 1.29. Comparison of glutathione-sensitivities of N-methylthio β-lactam 30,  
N-ethylthio β-lactam 83, and N-sec-butylthio β-lactam 88 in the presence of S. 
aureus. 
 
In fact, a plot of the reported cytosolic concentrations of glutathione in bacterial species, 
versus the antibacterial activities our lactams have against these microbes, follows an 
inversely linear dependency. Although we now recognized that high cytosolic levels of 
glutathione could protect cells  from the inhibitory effects of the lactams, we  still  did  
not  have  any  idea why the β-lactams  possess antibacterial capabilities against those 
susceptible microbes having low  (or  no)  glutathione. In effect, we needed to identify a 
viable cellular target in these bacteria associated with the observed antibacterial activity. 
For this, we synthesized β-lactam derivative 99 having a transferable, but resin-bound 
alkylthio moiety, that could be used to ‘ﬁsh’ for potential targets in bacterial ﬂuids 
(Figure 1.30).  
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Figure 1.30.  Identiﬁcation of coenzyme A from S. aureus lysate using a resin-bound 
N-thiolated β-lactam, 99. 
 
This resin-bound lactam was added directly into cultured S. aureus lysate, and afterward 
the lysate was extracted with ethyl acetate. In the extract, we found the anticipated N-
protio lactam released from the polymer. The solid content was reduced chemically with 
diisobutylaluminum hydride and to release the cellular component(s) that had been 
thiolated by the β-lactam 99 and temporarily bound to the polymer bead through a 
reducible disulﬁde linkage. HPLC analysis of the product mixture revealed a predominant 
new cytosolic target of the lactams, a small cytosolic thiol known as co-enzyme A (CoA). 
CoA is a low molecular weight, nucleotidic thiol found predominantly in the cytoplasmic 
ﬂuid of S. aureus and several other important pathogenic microbes including Bacillus and 
Micrococcus species.
17
 In  addition to  being a  required cofactor in  many  enzymatic 
processes in both prokaryotic and eukaryotic cells,  CoA also  serves as  an  effective  
replacement for  glutathione as  the redox ‘ballast’ protecting the cell from damage by 
reactive electrophiles and oxidants such as  reactive oxygen  intermediates. The  bacteria 
containing   the  highest   levels  of   CoA   in   their  cytosol,  namely, Staphylococcus, 
Bacillus,  and  Micrococcus, are also those that happen to have  the lowest concentration 
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of (or  no)  cytosolic glutathione,  and are  thus most susceptible to the growth inhibitory 
effects of N-alkylthio β-lactams. It was not yet clear whether the CoA thiol in the 
cytoplasm directly reacts with the N-thiolated β-lactams. We have observed 
experimentally that small cellular thiols including CoA, glutathione, and cysteine have no 
propensity on their own to cleave the N-organothio side chain off the lactams at 
physiological pH.  We suspect that there must be assistance in those bacteria affected by 
the β-lactams to cause the S-sulfenylation of CoA and the effects derived downstream 
from this event. This coincided with our ﬁndings that the N-thiolated β-lactam 
aggressively inhibits the uptake of acetate, and thus blocks fatty acid biosynthesis, in S. 
aureus. While there is strong likelihood that these ‘thiolating’ β-lactams  produce  
multiple inhibitory effects on  thiol-dependent enzymatic pathways, the ﬁnding that 
coenzyme A  is a  primary target of  N-thiolated β-lactams  brought  further  attention to 
CoA and, speciﬁcally, CoA-dependent  processes, as  a  viable target for the development 
of antibacterial drugs. 
 
1.9.   Studies on the effect of lactams on the redox buffer. 
Thiol-based redox buffer systems are present in all cells, and are required to maintain 
stasis in the cell as well as to intercept undesired chemicals that are detrimental to cellular 
components. This includes alkylating agents and reactive oxygen species that are highly 
damaging to proteins, nucleic acids, and cofactors. The redox buffer consists of an 
equilibrium mixture of a small sulfhydryl-containing molecule (as the reducing agent) 
and its disulﬁde counterpart (as the oxidant).  Typically, the concentration of free thiol in 
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these cytosolic buffers is high (often millimolar). The unusually high concentrations of 
CoA in Staphylococcus and Bacillus stems from the role CoA play in the redox buffer of 
these particular microbes, in place of glutathione.  The relative levels of  ‘reduced’ CoA 
(as the free  thiol) versus ‘oxidized CoA’ (CoA disulﬁde) are controlled  by  CoA  
disulﬁde  reductase,  a  protein  that  contains a cysteine residue and a  non-covalently 
bound  ﬂavin molecule. Reduction of CoA disulﬁde to the reduced CoA thiol occurs 
through thiol-disulﬁde exchange with the active site cysteine, followed by ﬂavin-
mediated hydride transfer from NADPH to reduce the cysteine-CoA disulﬁde bond and 
regenerate the active site. Despite some similarity, coenzyme A disulﬁde reductase is 
substantially distinct in its mechanism and substrate (disulﬁde) selectivity compared to 
glutathione disulﬁde reductase (that regulates glutathione-based redox). The correlation 
between the antibacterial activity of the N-alkylthio β-lactams and the CoA-based redox 
in S. aureus (and other microbes) led us to investigate whether the lactams were 
interacting with the catalytic capabilities of CoA disulﬁde reductase. In particular, we 
suspected that CoA reductase could be sulfenylated on its catalytically active cysteine by 
alkylthio transfer from the N-thiolated β-lactam. However, our experiments determined 
that neither lactam 30, nor the CoA-alkyl disulﬁde formed from 30 reacting ﬁrst with 
cytosolic CoA, had any measurable inhibitory effect on CoA reductase activity. Thus, it 
appears that even if CoA reductase’s cysteinyl thiol group is sulfenylated, the formation 
of this mixed disulﬁde may be inconsequential on cell stasis or catalytic function of CoA 
reductase. 
Since the CoA thiol-redox buffer is  not perturbed  by  the  N-alkylthio β-lactams , we  
considered the  possibility that the mixed CoA-alkyl   disulﬁdes  formed by  sulfenylation  
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of  CoA  by  the N-thiolated  β-lactams  might interact with  CoA-dependent enzymes 
that regulate bacterial fatty acid  biosynthesis. The most obvious of these is β-ketoacyl-
acyl carrier protein synthase III (FabH). Work by our  collaborator, Kevin  Reynolds, had 
earlier reported that mixed CoA-alkyl  disulﬁdes (prepared synthetically) can  inhibit 
enzymatic activity of  these  proteins  in  solution, in  a  structure-dependent manner,  but  
that  these  disulﬁdes had no  antibacterial  activity when tested against the microbes. The 
rationale for this was that the anionic character of the disulﬁdes prevented them from 
passing through the bacterial membrane, to where the enzyme is in the cytosol. These 
disulﬁdes, generated within the cytosol, have however been found to inhibit β-ketoacyl-
acyl carrier protein synthase III (FabH), a key enzyme in type II fatty acid biosynthesis. 
Moreover, the selectivity these disulﬁdes display toward a particular FabH protein is 
highly dependent on the structure of the alkyl residue, which of course, is directly derived 
from the N-alkylthio β-lactam. This may further explain the variation in antibacterial 
activities seen among the different N-alkylthio β-lactams and microbes. Further 
investigations on the involvement of FabH, and other putative FAS-related proteins, are 
an active interest of ours in more fully elucidating the mechanism, or mechanisms, of 
action, of these intriguing antibacterial agents. It  is  intriguing to  compare  the properties 
of  these N-thiolated β-lactams  to  those  of  the natural substance allicin, from freshly 
crushed garlic  cloves.  In addition to exhibiting activity against a wide range of bacteria, 
allicin also shows antifungal, antiviral, antiparisitic, and anticancer properties. Like the 
N-thiolated β-lactams, allicin displays the strongest activity against those bacteria that 
express low levels of glutathione, and blocks fatty acid biosynthesis.  Likewise, disulﬁde 
100, acting as a generator of CoA-methyl disulﬁde in the cytosol, and 101 are effective 
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inhibitors of FabH that may have some similarities in their mode of action to the N-
thiolated β-lactams (Figure 1.31). 
 
Figure 1.31.  Inhibitors of FabH. 
 
1.10. Studies on whether extrogenous fatty acids affect antibacterial properties of N-
thiolated β-lactams. 
Recent published studies have suggested that the addition of exogenous fatty acids to 
growth media can circumvent the growth inhibitory effects of FAS-targeting compounds 
on bacteria. To determine if the antibacterial activity of N-thiolated β-lactams can 
likewise be overridden by exogenous fatty acids, we determined the MIC for MRSA 
strains cultured in the presence of oleic acid and Tween 80. These two fatty acid additives 
reportedly can overcome the in vitro inhibitory growth effects of certain fatty acid   
biosynthesis inhibitors, and if this was found to be also the case for N-thiolated β-
lactams, this could indicate severe limitations in clinical use.  The highly deadly clinical 
MRSA strain, USA-100, was cultured in growth media containing the fatty acids Tween 
80 and oleic acid. Analysis was done with several controls, including bovine serum 
albumin, vancomycin (a cell wall biosynthesis inhibitor), and triclosan (a FAS inhibitor). 
Results showed that the MIC of vancomycin remained   constant   and unaffected by   the 
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supplementation of growth media with fatty acids, while for triclosan the MIC value 
increased 100-fold and 500-fold in the presence of oleic acid and Tween 80, respectively. 
In stark contrast, the MIC of N-sec-butylthio β-lactam 88 had barely a two fold increase 
in the presence of either fatty acid additive.  This dictates deﬁnitively that FabH-mediated 
inhibition of FAS by N-thiolated β-lactams is only weakly circumvented by exogenous 
fatty acids.  This suggests that the lactams may offer a variety of parallel inhibitory 
effects on fatty acid biosynthesis that are not easily circumvented, as is found for other 
fatty acid biosynthesis inhibitors such as triclosan. 
These newer results thus suggest that N-thiolated β-lactams are not only unique among β-
lactam antibacterial agents, but also as bacterial FAS inhibitors. Consequently, N-
thiolated β-lactams may hold signiﬁcant potential for the treatment of deadly bacterial 
infections caused by MRSA or other pathogenic microbes. 
 
1.11. Development of nanoparticle-bound N-thiolated β-lactams.  
During the course of these investigations, we began to contemplate avenues to overcome 
the low water-solubility and chemical sensitivity of N-thiolated β-lactams when used as 
antibiotic agents. We have found that attempts to increase water-solubility of the 
compounds by the attachment of more polar side chains onto the lactam core led to 
signiﬁcantly lower in vitro antibacterial activities. In 2007, we  developed a procedure for 
preparing nanoparticles of the N-thiolated β-lactams, using a process known as emulsion 
polymerization.
18
  In  this method,  monomers such as  butyl  acrylate and styrene are  
suspended in  water,  in  the  presence  of  a  small amount of  emulsiﬁed agent  such as  
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sodium dodecylsulfate, and a  water-soluble  free   radical  initiator is  then added with 
rapid stirring. The antibiotic drug can be added to this mixture prior to addition of the 
radical initiator, either as a free drug (to encapsulate the drug into the polymeric matrix), 
or as an O-acrylated derivative (to attach to the polymeric backbone, as shown in Scheme 
1.10). 
 
 
Scheme 1.10. Preparation of β-lactam-conjugated polyacrylate nanoparticles by 
emulsion polymerization. 
 
For the synthesis of these polymeric constructs, the acrylated antibiotic (generally 3 wt % 
of the solid contents of the solution) is premixed with a stirred mixture of butyl acrylate 
and styrene (in a 7:3 weight ratio). This mixture is then heated to 70° C in the presence of  
3 wt %  of  the surfactant (SDS), and  with  rapid stirring,  sodium persulfate  (1 wt %)  is  
added.  The  polymerization proceeds within a  few  hours to afford the drug-attached 
polymer  in   high  efﬁciency,  providing  polyacrylate  nanoparticles measuring  around  
45 nm  in   diameter  as   a  stable  aqueous emulsion.  Scanning   electron  microscopy  
showed  the   nanoparticles to  be  spherical  and  highly  uniform  in  size.  In vitro 
microbiological testing determined that these antibiotic-bound nanoparticles possess 
strong antibacterial capabilities against S. aureus, including MRSA, as well as B. 
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anthracis. Thus,  the  antibiotics preserved their strong activities  toward  these  microbes 
even  when contained  in  a  chemically bound form  within a polyacrylate  nanoparticle. 
Further investigations in our laboratory extended this methodology to glycosylated 
polyacrylate nanoparticles that carry within their matrix an N-thiolated β-lactam. In this  
case,  the β-lactam is tethered off of a protected monosaccharide bearing an acrylate ester 
moiety at one  of  its oxygenated  centers,  and this entire  unit  serves  as  a  co-monomer  
for  the polymerization. An example is shown below for 102, an N-sec-butylthio β-lactam 
acylated with a carboxylate-bearing glucofuranose (Figure 1.32).  Although it was  not 
clear if these large acrylates  would even  participate   in   radical    polymerizations    
under   strictly   aqueous conditions, we  were pleased to obtain the desired  nanoparticle 
emulsions employing the standard  3 wt %  of  SDS and 1 wt %  of potassium  persulfate. 
Dynamic light scattering experiments conﬁrmed the formation of these nanoparticles, 
again with an average diameter of 45 nm, with high uniformity in particle size 
distribution. These emulsiﬁed, glycosylated nanoparticles had promising in vitro  
bioactivities  against  both  MRSA  and  B. anthracis. 
 
Figure 1.32.  Glycosylated β-lactam 102. 
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1.12. Antifungal activity of N-thiolated β-lactams. 
In the literature preceding our work,   it was rare to ﬁnd any β-lactam compounds that had 
the ability to alter the growth of fungi. Even in  these  instances, the  concentration of  
compound needed  to  induce deleterious effects on  a  fungal cell  far  exceed those  
typically seen  for  bacteria,  and the  modes in  which the compounds act  as growth 
inhibitors are  unknown.  Certainly, it  is distinct to  that of  their  antibacterial properties, 
given that  the traditional  β-lactam  antibiotics  affect cell  wall   cross-linking by 
transpeptidases, and fungal cells  do  not possess  these  enzymes. Moreover, the naturally 
occurring β-lactams are designed by fungi for protection against bacterial invaders, and 
thus are speciﬁcally constructed to act on bacterial enzymes, not fungal. Nevertheless, the 
ﬁnding that  N-thiolated β-lactams  those carrying  N-sulfenyl side chains inhibit cellular 
events within the cytoplasm,  and not within  the cell  wall,  by  blocking the formation of  
lipid bilayers needed for cellular compartmentalization, gave  us reason to  consider 
whether similar effects could be found in eukaryotic cells.
19
 
The other intriguing aspect  of  how the  N-thiolated  β-lactams function biochemically is 
that they only  appear to affect microbes with  low  glutathione levels, and  high amounts 
of  coenzyme A (required for  fatty  acid biosynthesis). Candida produces high 
intracellular levels of free thiol, including coenzyme A. Our laboratory carried out   some 
initial in vitro screenings of representative N-organothio β-lactams   against Candida and 
other common fungi, and determined that some of the compounds have signiﬁcant 
antifungal activity. The effects are fungistatic, not fungicidal, and are concentration-
dependent. Moreover, the compounds exert their static effects on fungi by creating a 
‘scrambled eggs’ morphology on cytoplasmic membranes. The structure-bioactivity 
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trends and the probable mode of antimicrobial action of the compounds appear to run 
parallel between the bacterial and fungal cell lines, with subtle differences.  
In our antifungal screening, we examined a dozen representative β-lactam analogs against 
seven  Candida species,  including Candida albicans, Candida glabrata, Candida 
tropicalis, Candida parapsilosis,  Candida lusitaniae, Candida kefyr, Candida utilis,  and  
the resilient Candida krusei.  Some structural trends within these lactam analogs were 
noted. For instance, replacing the C3-methoxy for an acetoxy or phenoxy lowered 
bioactivity. For C4 mono-halogenated aryl derivatives, those having ﬂuorine attached to 
the aryl moiety had the weakest antifungal activities. Otherwise, it did not really matter, 
which of the halogens is present on the ring, as long as it was (preferably) ortho or meta 
to the β-lactam moiety. Thus, para-substituted aryl rings showed the lowest levels of 
bioactivity. Additionally, it seems that multiple halogens on the aryl ring increased 
bioactivity, with again, those halogenated at the ortho or meta centers   being   preferred.  
The most signiﬁcant structural dependency, however, in the case of anti-Candida 
properties, was found to be the nature of the organothio moiety. Whereas for antibacterial 
activity toward MRSA, the preferred N-substituent was sec-butylthio, for Candida, the 
N-methylthio was notably better. Among the analogs tested, the strongest antifungal 
compound was 17. Minimum inhibitory concentration of 30 against C. albicans was 8 
mg/ml, similar to that of the clinical antifungal drug: clotrimazole. The MIC value 
increased with time, as  incubation time increased from 24 h  to 48 h,  indicative of  a  
static control by  the antibiotic (decreasing as its  concentration incrementally  diminished  
over time). MIC values were 16 mg/ml for Aspergillus niger (tested on potato dextrose 
agar) and 32 mg/ml for Saccharomyces cerevisiae (on YM agar).  As in the antibacterial 
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studies, stereochemistry of the lactam (either cis/trans relative stereochemistry, or 
absolute stereochemistry) was a negligible factor. The enantiomeric β-lactams (+)-78 and   
(-)-78 produced similar growth inhibition zone sizes against all of the Candida tested. 
Transmission microscopic imaging of C. albicans cells exposed to these lactams 
indicated signiﬁcant structural deformation to organelles due to disruption of 
mitochondrial and other intracellular membranes. The lack of cell division indicated a 
barrier caused by the β-lactams to allow the cell to maturate and replicate. None of these 
effects were observed for the untreated cells. From these data, we proposed that the β-
lactams exert their antifungal properties in much the same way as they act as 
antibacterials, by reacting within the cell via sulfenylation. Trypan blue staining assays 
indicated that the fungal cells remained viable after treatment, indicative of a static 
property of the β-lactams (as for bacterial cells). Extraction of treated cells with an 
organic solvent led to the recovery of the corresponding N-protio β-lactam, derived from 
dethiolation of the N-alkylthio β-lactam. This compound showed no antifungal properties 
of its own, even after prolonged exposure to fungal cells, and its presence allowed us to 
conﬁrm that it is the N-organothio substituent and not the β-lactam ring that is 
responsible for anti-fungal activity. The fact that the conformationally strained β-lactam 
ring remains intact while the alkylthio side chain moiety is quickly clipped off the β-
lactam nitrogen inside the fungal cell supports this. The other substituents on the β-
lactam ring provide for only minor perturbation of the bioactivity, which is likely the 
result of differences in navigating through the cellular membrane of the fungal cell, and 
entering the cytoplasm. The slightly different SAR features of  the  β-lactams   by  S. 
aureus   versus  Candida, and the preference for an  N-methylthio moiety (for  Candida) 
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versus an  N-sec-butylthio  (for  MRSA), could  indicate  minor differences in  the 
cellular targets or mode of action of the lactams in each cell type. 
 
1.13. Anticancer activity of N-thiolated β-lactams. 
Several studies have also been reported from our laboratories on the anticancer properties 
of the β-lactams.20-23 The ﬁrst of these, published in 2002, showed that N-methylthio β-
lactams can induce apoptotic behavior in a number of cancer cell lines, including human 
breast, prostate, leukemia, and head-and-neck.  The   most powerful compound 30 caused 
DNA damage and the inhibition of DNA replication in Jurkat T cells.
20
  The result of this 
was activation of p38 mitogen-activated protein kinase, as well  as S-phase arrest and 
cellular apoptosis. We found that p38 protein played a key role in apoptotic induction, as 
a result of DNA damage, and led to caspase activation. Along  with  caspase-8 activation, 
we  observed cleavage of Bcl-2 family protein Bid, and release of cytochrome C from  
the mitochondria prior to caspase activation, events that all point to  apoptotic 
commitment  by  the  cell  in  response to  the β-lactam. Activation of caspases-9 and 
caspase-3 along with PARP cleavage also occurred. There was also a noticeable decrease 
in the membrane permeability, which occurs late in apoptosis. These events were found 
to be   both   time-dependent and β-lactam concentration-dependent,   as  expected    for 
caspase-induced apoptosis.
21 
N-Thiolated β-lactams  do   have   selective  activity  toward   
inducing cell death in a variety of important human cancer cell lines, in  a  time and  
concentration-dependent  manner.  Precisely how duplex DNA is cleaved in the presence 
of the β-lactam (and not necessarily by the β-lactam itself), however, was not deduced. 
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All we were able   to determine was that DNA cleavage occurred in a time-dependent and 
concentration-dependent manner, before stagnation occurred in the S-phase cell cycle, 
and in a manner inversely proportional to the size of the organothio side chain of the β-
lactam used. This same trend was observed for the rate of phosphorylation of p32 protein, 
which occurs upstream of caspase activation and caspase-induced apoptosis.  
Signiﬁcantly, the N-protio analog (lacking the N-methylthio moiety) was completely 
inactive toward the induction of caspase-3 or PARP cleavage in the leukemia Jurkat T 
cells.  There are several new things we learned from this study. Clearly, the role of the 
sulfur group in cancer cell- apoptosis is critical, as has been found for the antimicrobial 
properties of these β-lactams. Among the selection of N-thiolated β-lactams initially 
examined, the N-methylthio derivative exerted the strongest potency compared to the N-
benzylthio, N-ethylthio, or N-butylthio analogs. Thus, there is a structure-activity 
dependency of the alkylthio substituent, although the trend is not parallel to that observed 
for either the antimicrobial or antifungal bioactivities. This can be an important 
consideration in discerning the use of the β-lactams toward prokaryotic versus eukaryotic 
cells.  The conclusion of this study was that, for the ﬁrst time, β-lactam antibiotics may 
have a primary role in cancer chemotherapy. 
In a follow-up study, we investigated this further, focusing on whether the N-methylthio 
β-lactams could distinguish between cancerous versus normal cells in the apoptotic 
effects. The  lead compound, β-lactam 30, was ﬁrst indeed shown to selectively induce 
apoptosis in  human leukemic Jurkat T cells,  but not in  non- transformed, immortalized 
human natural killer (NK) cells.
22
  Further examination identiﬁed an  even more  potent 
analog, N-methylthio β-lactam 24 having a nitrophenyl moiety at C4. All of the β-lactams 
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having an N-methylthio side chain inhibited colony formation of human prostate cancer 
cells.  Most signiﬁcantly, β-lactam-induced apoptosis occurred selectively in Jurkat T and 
simian virus 40-transformed cells, but not in NK or parental normal ﬁbroblast cells. 
More  recently, we  had the opportunity to  evaluate  additional β-lactam analogs having 
branched side chains off the C3 center of the lactam, ﬁrst for  apoptosis-induction and 
then for  in  vivo  inhibition of  breast tumor progression in  mice. It  was  determined that 
the same effects observed for the β-lactams in vitro also  occur in vivo, in retarding the 
growth of the xenograph and in inducing DNA  cleavage and apoptosis. The conclusion 
of this series of investigations is that N-thiolated β-lactams may have utility in cancer 
control or prevention, showing no deleterious effects in the mice, or any cellular toxicity 
to normal cells in vitro. Mice treated with the β-lactam displayed a 50% decrease in 
tumor size with no visible indications of toxicity.  We conﬁrmed that this reduction of the 
tumor growth is directly due to apoptosis induced by the β-lactam.  Although the details 
of the mechanism for this activity is not clear, the presumption is  that  the  high 
glutathione levels  maintained in normal mammalian cells  may provide  protection to  
apoptotic effects of  the  β-lactams  that are  otherwise found to  occur,  for  unknown 
reasons, in  transformed or  tumor cells.
23
  From  our  initial studies  in  xenografts,  no   
observable  deleterious  effects  of  the β-lactams  were found at relatively high 
concentrations (compared to antibacterial levels). 
In addition to the potential anticancer utility, it is important to point out that the most 
active compound in the in vitro antitumor experiments, β-lactam 30, exerts its effects at 
50-100 mM, which is about 100-200 times the bacterial MIC of our most potent β-lactam 
analogs. At these concentrations, and several fold higher, no cellular toxicity was 
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observed for normal human ﬁbroblasts, indicating that the selectivities between healthy 
human tissue and bacteria are signiﬁcant and that there should be no concerns of 
implementing the β-lactams for treatment of infections.  However, much more study on 
this would obviously be necessary, including systemic toxicities and side effects at 
therapeutic levels. 
 
1.14. Conclusions. 
The initial discovery in our laboratory during the mid-1990s of the antibacterial 
properties of   N-thiolated β-lactams came as a complete surprise. Over  the course of our  
investigations, starting  with  structure-activity  proﬁling,  followed by  exploring  the 
spectrum of bioactivity, computational modeling studies, cellular effects,  and  
mechanism of  action,  we  have  learned a  great deal about these interesting  molecules.  
In particular, their bacteriostatic properties on select pathogenic microbes, unique SAR 
patterns, and effects on cellular targets or processes, do in fact differ in major ways to 
other β-lactam antibiotics or to other antimicrobials altogether. While how these N-
thiolated β-lactams exert their microbiological effects is still not completely understood, 
they clearly affect cellular processes associated with coenzyme A and lipid biosynthesis.  
The greatest surprise, though, were the bioactivities observed for these β-lactams against 
eukaryotic cells, particularly yeast and cancer cells.  In  many ways,   our   ﬁndings stand  
in  the face  of  past  and  present practices within the pharmaceuticals  industry, where   
the  advent  of  drug  resistance  in bacteria  for a  particular  antibiotic is  rapidly 
followed with  the attempt  to  ﬁnd ever-more  strong and  broad-spectrum variants that 
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can  still perform clinically.  This of course has led steadily to the problems of antibiotic 
resistance, ﬁrst in our hospitals, then throughout our communities. This  brings up  the 
entire question of  whether antibiotics  should be  used at all,  whether drug  discovery  
for infectious agents  should escalate, or back  off,  in creating more effective agents. The 
steady increase of bacterial drug resistance, and the continuous call for effective new 
antibiotics having alternative mechanisms of action, ensures that this discussion will   
continue.  This is where the narrow-spectrum, bacteriostatic N-thiolated β-lactams may 
ﬁnd a unique niche. Moreover, their incorporation into organic nanoparticles that enhance 
bioactivity and perhaps bioavailability may enable further expansion of their usefulness 
in the treatment of infections. These areas are among those that our laboratory hopes to 
further explore and develop. 
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CHAPTER 2: MODE OF ACTION OF N-THIOLATED β-LACTAMS AS 
ANTIBACTERIALS. 
 
2.1  Staphylococcus aureus.  
Staphylococcus aureus (S. aureus) is a versatile and adaptable human pathogen, 
exhibiting multi-modal pathogenesis and acquired resistance to almost every antibacterial 
therapy introduced in the last six decades.  
S. aureus is a human commensal pathogen carried on the skin or in the nasal passages of 
people and animals. Most of the human population is colonized by S. aureus, and are not 
aware of it. Evidence has shown that nasal secretion containing hemoglobin might 
promote S. aureus nasal colonization, followed by an infection.
1 
Methicillin-resistant Staphylococcus aureus (MRSA) infection is caused by a strain of S. 
aureus bacteria that has become resistant to the β-lactam antibiotics commonly used to 
treat ordinary staph infections. MRSA infections are primarily prominent in 
immunocompromised people, although infections in immunocompetent people are also 
steadily becoming quite common.
  
  
Hospitals are still infested with MRSA and by the last decade, a single strain, USA-300, 
has emerged as a menace in the community.
2
 Community-acquired (CA-MRSA) 
infections caused by USA-300 have been steadily increasing in number, while the 
occurrence of hospital-acquired MRSA (HA-MRSA) infections caused by USA-100 is 
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declining.
3,4
 USA 300 is the major cause of the alteration in epidemiology of MRSA 
infections in the United States, and now accounts for the majority of skin and soft tissue 
infections (SSTIs) occurring in operating rooms.
5
 Lately, it has become difficult to 
distinguish between CA-MRSA and HA-MRSA. The HA-MRSA isolates are now known 
to be prevalent in the community, especially among adults. It is assumed that the 
presence of CA-MRSA strains in hospitals might be responsible for the decreasing non-
β-lactam antimicrobial resistance rates to macrolides, tetracyclines, quinolones, 
lincosamides, and trimethoprim-sulfamethoxazole, providing increased options for the 
treatment of infections caused by these MRSA strains.
6,7 
The major classes of antimicrobials used for the clinical treatment of S. aureus and their 
mode of action are listed as follows in Table 2.1.
8, 9, 10,11,12,13
  
 
Table 2.1. Antibacterials and their mode of action. 
Mode of action Antimicrobials 
Cell wall synthesis inhibitors Vancomycin, Penicillin 
Membrane disruption agents Daptomycin 
DNA synthesis inhibitors Fluoroquinolones such as Ciprofloxacin, 
Levofloxacin, and Moxifloxacin 
Transcription inhibitors Rifampicin 
Translation inhibitors Aminoglycosides (e.g.Gentamicin) and  
macrolides (e.g. Erythromycin) 
Fatty acid synthesis inhibitors Triclosan, Platencin and Platensimycin 
Structures of the drugs mentioned above are shown below in Figure 2.1. 
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Figure 2.1. Structures of different antimicrobials for S. aureus. 
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CA-MRSA are usually non–multidrug resistant and frequently carry SCCmec allotypes 
IV and V (an allotype is an allele which may be detected as an antigen in another 
individual of the same species that is part of a plasma protein as an antibody, eg 
histocompatibility antigens, immunoglobulins),
 14
 which are smaller than the Types I-III 
SCCmec present in HA-MRSA, and thus lack resistance genes other than mecA. The 
antibiotic gene mecA is believed to be responsible for resistance to methicillin and other 
β-lactam antibiotics.15, 16 
In a study published in Clinical Microbiology Reviews, CA-MRSA strains obtained from 
patients with nasal colonization were tested by exposing the strains to fluoroquinolones.
5
 
It was found that β-lactam resistance increased with fluoroquinolone exposure.  
The Figure 2.2 shown below highlights that Tryptic Soy Broth (TSB) containing a 
subinhibitory concentration of ﬂuoroquinolones, either ciproﬂoxacin or levoﬂoxacin, 
resulted in an increase in the number of colonies that would grow on nafcillin agar, as 
compared to cultures grown in TSB without ﬂuoroquinolones.17 Colony-forming unit 
(CFU) is used to determine the number of viable bacterial cells in a sample per 
mL; Nafcillin is a narrow-spectrum β-lactam antibiotic.18 
Von Eiff et. al. have described 3 patterns of S. aureus transfer via humans: a) those who 
always carry the S. aureus strain, b) those who carry the organism occasionally with 
changing strains, and c) a small fraction of people who do not carry S. aureus.
19
 It was 
previously believed that the transmission of MRSA was unidirectional from human to 
animal (reverse zoonotic), but evidence now shows that the MRSA infections can also be 
transmitted from animal to human (zoonotic) too.
20
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Figure 2.2. Tryptic Soy Broth (TSB) containing ciproﬂoxacin on nafcillin containing 
agar. 
 
2.2. N-Thiolated β-Lactams.  
Antibiotics are very important to humans and are not limited to treat infections but have 
also garnered a great deal of research. Synthesis of an antibiotic that is unique in its mode 
of action or in preventing bacterial resistance is a challenging task, but nonetheless, is 
constantly evolving.
 
Though it has been reported that MRSA isolates are resistant to all 
available penicillins and other β-lactam antimicrobial drugs,21 N-thiolated β-lactams do 
not follow the same trend of resistance. Figure 2.3 below depicts the chemical structure 
of N-thiolated β-lactam. 
 
Figure 2.3.  Structure of an N-thiolated β-lactam. When R’=CH3 it is known as an 
N-methylthio β-lactam. 
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N-Thiolated β-lactams comprise one such novel class of antibiotics which mostly targets 
the Staphylococcus species, including MRSA strains. This new class of antibacterial 
compounds was introduced in the early 2000’s and extensive research has been done on 
them in the Turos laboratory. They have interesting biological activities, as described in 
detail in Chapter I.  
 
2.3. Chemistry of N-Thiolated β-Lactams. 
These novel N-thiolated β-lactams lack the ionizable side chain of penicillin and are 
highly lipophilic molecules compared to all the previously used β-lactam antibiotics, 
including penicillins, cephalosporins, penems, carbapenems and monobactams. Penicillin 
was first discovered by Alexander Fleming in 1928. Extensive use of penicillin during 
World War II caused the development of resistance to the drug. Thus, other β-lactam 
antibiotics were being synthesized in order to combat infectious diseases while 
overcoming resistance and increasing the spectrum of activity. The core structure of 
penicillin is shown below in Figure 2.4 with R being the variable group. If R=CH2Ph it is 
known as Penicillin G. Amoxicillin is an antibiotic belonging to the penicillin family. 
Other members of this family include ampicillin, piperacillin, ticarcillin and several 
others. Like other antibiotics in the penicillin category, amoxicillin cell death prevents 
bacterial growth and cell wall maintenance, by inhibiting the synthesis of the cross-
linkage of the peptidoglycan in the cell wall, thereby causing cell death. Like penicillin, 
amoxicillin is also susceptible to degradation by β-lactamase producing bacteria and thus 
clavulanic acid is often prescribed along with it, as a β-lactamase inhibitor.22 Clavulanic 
acid itself, though, has no significant antibacterial activity. Figure 2.4 below compares 
   
70 
 
the structure of penicillin, amoxicillin and N-thiolated β-lactams. Penicillin and 
amoxicillin have one and three ionizable groups respectively, while N-thiolated β-lactams 
contains no ionizable groups. 
 
Figure 2.4. Ionizable group comparison between penicillin, amoxicillin and N-
thiolated β-lactams. 
 
Structure-activity studies in N-thiolated β-lactams have demonstrated that the N-
organothio group is essential for the antibacterial activity. Unlike the penicillins, which 
inhibit bacterial cell wall synthesis, N-thiolated β-lactams inhibit Type II Fatty Acid 
Synthesis (FASII) by FabH-mediated inhibition. This hypothesis, which will be further 
discussed, holds true considering that these lactams do not cause any morphological 
defects in the bacterial cell wall. 
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FabH, which is also known as β-ketoacyl-acyl carrier protein synthase III, belongs to the 
family of condensing enzymes involved in bacterial fatty acid biosynthesis type II and is 
considered an essential catalyst. FabH is encoded by the fabH gene, and is believed to 
catalyze the condensation. More explanation regarding FAS is provided in the next 
section.
23 
 
2.4. Fatty Acid Synthesis Type II. 
Fatty acid synthesis, also known as fatty acid biosynthesis, is an essential cellular process 
in plants, bacterial systems, animals and humans.
24  
In bacteria, this process is known as 
FAS type II, and is responsible for the formation of fatty acids from acetyl-
CoA and malonyl-CoA. The structures of acetyl-CoA and malonyl-CoA are given below 
in Figure 2.5. 
 
Figure 2.5. Structure of acetyl-CoA and malonyl-CoA. 
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FAS II involves the help of a large multi-enzyme complex called fatty acid synthase as an 
essential enzymatic unit. Fatty acid synthase is a polypeptide having multiple domains, 
each having distinct enzyme activities required during the process of fatty acid 
biosynthesis.  In animals, the process is known as FAS type I with fatty acid synthase 
being a single multifunctional polypeptide that catalyzes all of the reactions in the 
elongation pathway, while for the Type II pathway, unique enzymes catalyze each step. 
Thus the type II system organization is distinct from the Type I system, and offers unique 
sites for selective inhibition by antibacterial agents.
25  
Fatty acids, in general, are long 
hydrocarbon chain carboxylic acids that are the building blocks of fatty esters. They are 
highly non-polar and insoluble in water and used for energy and as metabolic precursors 
for biological membranes in most types of cells. The hydrocarbon chain length may vary 
from 10-30 carbons, differing in units of two carbon units.  Four different fatty acids are 
shown in Figure 2.6. 
 
 
Figure 2.6. Structures of four fatty acids.  
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Fatty acids are also precursors to lipids that include fatty esters and triacyl glycerides. In 
case of the latter, glycerol is per-acylated with three molecules of fatty acids to form a 
triglyceride. For example, triolein is composed of three molecules of oleic acid 
(C18H34O2) as the acyl residues on a glycerol framework shown in Figure 2.7. 
 
Figure 2.7. Structure of Triolein. 
 
Branched fatty acids are common in many Gram-positive bacteria, while Gram-negative 
bacteria are composed of predominately straight chain fatty acids.  
In bacteria, fatty acid composition is thought to be genetically determined and highly 
conserved. Significant changes in bacteria only take place over a considerable period of 
time. The same species of bacteria from different parts of the world have similar fatty 
acid composition as long as the environment it is growing in is similar. Thus, fatty acid 
composition of bacteria partly depends on the nature of the medium and the conditions 
under which the culture is grown.
26 
Scheme 2.1 below shows the reaction pathway and the reaction intermediates in bacterial 
FASII biosynthesis. In the type II system, fatty acid elongation occurs by increments of 
two carbons by the Claisen condensation of malonyl-ACP (acyl carrier protein) with 
acyl-ACP. These ACPs are small, soluble proteins, acidic in nature, that move the 
elongating chain between enzymatic units. The condensation reactions are catalyzed by 
three discrete enzymes (FabB, FabF, and FabH) and a number of other enzymes (FabI, 
FabG and FabZ) that perform additional reactions within the pathway. For instance, 
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bacteria may require oxidation changes at specific carbons in the acyl chain. This occurs 
in the chain elongation cycle, carried out by enoyl‐ACP reductase by FabI, or generating 
β-hydroxyacyl-ACPs by FabG, or dehydration of β-hydroxyacyl-ACPs by gene FabZ.27  
 
Scheme 2.1. Reaction sequence in fatty acid biosynthesis. 
 
Fatty acid chain elongation proceeds linearly by first activating ACP, which uses its free 
sulfhydryl group to thioacylate acetyl coenzyme A (acetyl CoA) and malonyl coenzyme 
A (malonyl CoA) and links them by condensation to form a β-keto thioester. This is then 
subjected to further condensation, to add two extra carbons to the growing acyl chain 
through each cycle.
28
 Alternatively, acetoacetyl-ACP can be reduced by NADPH to -
hydroxyacetyl-ACP. NADPH is used as a reducing agent and is the reduced form of 
nicotinamide adenine dinucleotide phosphate (NADP+). NADP+ is a coenzyme used in 
anabolic reactions, such as lipid and nucleic acid synthesis.
29
 Figure 2.8 depicts the 
structure of NADP. 
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Figure 2.8. Structure of nicotinamide adenine dinucleotide phosphate. 
 
-Hydroxyacetyl-ACP is then dehydrated via the enzyme -hydroxyacetyl-ACP 
synthase, producing crotonyl-ACP. Finally crotonyl-ACP is reduced by NADPH to 
produce butyryl ACP, via the reducing enzyme enoyl-ACP reductase.
30 
 
The pyruvate made from glycolysis gets converted into S-acetyl-CoA, which then goes 
through the Tricarboxylic Acid Cycle (TCA Cycle) in the mitochondria. This shows how 
FAS, the TCA cycle, glycolysis and pyruvate metabolism are all interconnected via S- 
acetyl-CoA.  
Within this concept, N-thiolated β-lactams in the presence of cytosolic S-CoA is 
postulated to form an alkyl-CoA mixed disulfide via thiol-transfer. Shown below in 
Scheme 2.2 is a general reaction of a proposed thiol transfer from the N-thiolated β-
lactam onto the thiol group of Coenzyme A. 
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Scheme 2.2. Proposed S-thiolation of coenzyme A by an N-thiolated β-lactam. 
 
These alkyl-CoA mixed disulfides can then, hypothetically, inhibit any of these processes 
discussed above, and prevent bacterial growth or survival.
31   
 
 
2.5.  Results and discussions. 
2.5.1. Synthesis of N- Thiolated β -Lactam 88. 
The synthetic pathway to prepare the C3 substituted N-thiolated β-lactam analogs is 
depicted in Scheme 2.3 and has been previously reported.
 31,32,33,34
 It involves a five stage 
sequence of reactions initiated by the synthesis of N-(4-methoxyphenyl) imine from 
benzaldehyde and p-anisidine. Methoxyacetyl chloride and the imine are coupled 
together by Staudinger reaction to produce exclusively the cis-substituted β-lactam as a 
racemic product mixture. Oxidative cleavage of the p-anisyl moiety from the β-lactam 
nitrogen center by ceric ammonium nitrate yields the N-protio β-lactam. This step is then 
followed by reaction with N-(sec-butylthio) phthalimide to yield the N-sec-butylthio β-
lactam 88.  
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Figure 2.9. N-sec-butylthio β-lactam 88. 
 
 
Scheme 2.3. Synthetic pathway to make lactam 88. 
 
2.5.2.  Mode of Action of N-Thiolated  β-Lactams. 
Earlier studies in the Turos lab have shown that N-alkylthio β-lactam compounds are 
highly selective towards Staphylococcus and Bacillus microbes.
33,34,35
 Unlike penicillin or 
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vancomycin, which kills bacteria by inhibiting cell wall crosslinking proteins and affords 
a broad spectrum of bactericidal activity, these lactams are bacteriostatic in their behavior 
and act through a different mechanistic mode of action.
31 
As discussed earlier, N-
thiolated β-lactams inhibit fatty acid synthesis in Staph and Bacillus.  
Our previous studies have also suggested that N-thiolated β-lactams may target 3-
oxoacyl-acyl carrier protein synthase (ACP) III (FabH) either directly or indirectly 
36 
by 
reacting within the bacterial cell with the cofactor coenzyme A by transfer of the 
alkylthio chain to produce an alkyl-CoA mixed disulfide. It has been suggested that 
mixed disulfide inhibits FabH within its active site.
31
 Alternatively, the N-thiolated β-
lactam may transfer the thio alkyl moiety onto a cysteine sulfhydryl group in FabH to 
block its activity, but this appears to be a minor pathway. 
Drugs that target the type II fatty acid synthesis (FASII) pathway may be useful against 
superbugs like MRSA. It was reported in 2007, that targeting the FASII pathway in 
bacteria might have a promising future in developing novel antimicrobial drugs and a 
potential target for chemotherapy development.
37 
Fatty acid synthetase along with the 
other enzymes of fatty acid biosynthesis cycle represent molecular targets distinct from 
those in eukaryotic cells.  
Cerulenin is an antifungal antibiotic that inhibits FAS, and both a saturated fatty acid and 
an unsaturated fatty acid or branched-chain saturated acid are required to reverse the 
inhibition by cerulenin for either Escherichia coli or Bacillus subtilis.
38
 
It has also been reported that the disadvantage of antibiotics targeting the FASII pathway 
is that exogenous fatty acids might circumvent the inhibition of this pathway.
39 
It was 
found by Sophie Brinster from Université Paris Descartes that in presence of exogenous 
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fatty acids a few varieties of Gram-positive bacteria like streptococci, pneumococci, 
enterococci and staphylococci can overcome drug-induced inhibition of the FASII 
pathway. 
Moreover, there are free fatty acids found in the human body, in blood for example, and 
thus many bacteria are able to use them if they are unable to make their own fatty acids 
by the FAS type II cycle. 
Hence the next line of research was to check if addition of exogenous fatty acids to the 
culture media would have an effect on the antibacterial properties of N-thiolated β-
lactams against MRSA.  
 
2.6. Biological experiments and Discussion.  
The biological activity of N-thiolated β-lactam 88 against various S. aureus strains was 
studied by Katherine Prosen in Dr. Lindsey Shaw’s laboratory (USF Department of Cell 
Biology, Microbiology and Molecular Biology). To further elucidate the mode of 
acquired resistance of S.aureus to these compounds, mutant resistant strains of S. aureus 
were generated and cellular changes were studied. Some of the strains that were used in 
the study are shown in Table 2.2.
38 
These strains of S. aureus were screened for resistance using the disk diffusion assay 
method 
40, 41
 to elucidate the activity of the N-thiolated β-lactam 88. For all the strains the 
MIC 
42 
(minimum inhibitory concentrations, the minimum concentration of antimicrobial 
that is needed to prevent the growth of an organism.) were in between 0.4 to1 µg/ml. It 
was found from the zone table that  the zones was comparable, and there was no change 
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in the size of the zone of inhibition suggesting that the mode of action of the drug was not 
affected by intrinsic factors. 
Table 2.2. Mutant resistant strains of S. aureus. 
S. epidermidis RP62A  
S. aureus 8325-4  
S. aureus RN6390  
S. aureus SH1000  
S. aureus Newman  
S. aureus COL  
S. aureus UAMS-1  
S. aureus USA 100 635  
S. aureus USA 100 Mu50  
S. aureus USA 200 MRSA252  
S. aureus USA 300 Houston  
S. aureus USA 300 LAC  
S. aureus USA 300 FPR3757  
S. aureus USA 400 MW2  
 
Following this, in order to check if the addition of exogenous fatty acids to the culture 
media affects the anti-MRSA activity of N-thiolated β-lactam 88, 0.1% Tween 80 (a long 
chain fatty acid) and 0.01% oleic acid were added individually to the bacterial culture 
with the Staph strains, and the disk diffusion assay was run. Tween 80 was prepared as a 
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10% solution in 5% BSA and 0.01 % oleic acid was made as a 1% solution in 5% sterile 
BSA. Vancomycin (a cell wall inhibitor) was used as a control. It was seen that the zone 
of inhibition in the culture for the lactam 88 with Tween 80 had reduced significantly 
with all the strains, whereas the zones remained mostly consistent for most of the strains 
with Vancomycin. This implies β-lactam 88 activity is greatly affected by fatty acids. 
After this initial study, the 14 MRSA stains were cultured in growth media, in the 
presence of lactam 88, vancomycin, and triclosan, respectively by adding 0.1% Tween 
80, 0.01% oleic acid, or 0.5% Bovine Serum Albumin (BSA) in tryptic soy broth (TSB). 
BSA (used to dissolve Tween 80) and oleic acid were used as controls.
36 
It was observed that BSA, Tween 80, and oleic acid significantly reduced the MIC values 
for vancomycin, indicating that adding these additives in the assay might work 
collaboratively with vancomycin. The MICs of triclosan severely decreased by the 
addition of fatty acids, as triclosan is known to be a FAS II inhibitor.
42
 The MIC value of 
β-lactam 88 was expected to follow the same decrease as for triclosan since we believe 
that β-lactam 88 is also a FAS II inhibitor. The experimental data, however, revealed only 
a modest two-fold increase in MIC. Thus, the antibacterial effects of β-lactam 88 were 
only weakly circumvented in presence of exogenous fatty acids, unlike triclosan. Figure 
2.9 below shows the MIC (µg/ml) for Vancomycin, Triclosan, and β-Lactam 88. The data 
presented herein is for S. aureus USA 100 635 and each MIC was performed in triplicate. 
Previous studies on fatty acid inhibiting antimicrobials have shown that addition of fatty 
acids reduces the drug effects of triclosan. Other antimicrobials that target the 
condensation step in FAS lose efficacy too. However, lactam 88 did not do this and this 
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suggests that targeting a single enzyme or step of the fatty acid synthesis pathway may 
not be the primary target.
39, 44, 45 
 
Figure 2.10. MIC (µg/ml) for vancomycin, triclosan, and β-lactam 88 for S. aureus 
USA 100 635. 
 
Mutations are known to often cause antibiotic resistance in bacteria, thus, analyzing their 
frequencies in bacteria can help in figuring out not only the capability of the antibiotic 
agent to treat infections, but also the minimum dosage that could be required for best 
efficacy. A spontaneous mutation test was done on all 14 of these MRSA strains, and the 
mutation rate to lactam 88 was found to be comparable to other antimicrobials. This 
suggests that it may be used as a single therapy drug.  
Further on, the effects of prolonged exposure of lactam 88 on the Staph bacteria was 
studied. This was done by generating “2nd step” β-lactam-resistant mutants by exposing 
MRSA or MSSA (methicillin-susceptible S. aureus)  isolates on Tryptic Soy Agar plates 
containing 5 times the MIC of β-lactam 88.45 
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On exposure to this dose, MSSA isolates showed more than twelve fold decreases in 
mutation frequency compared to MRSA isolates. This strongly suggests that the 
resistance mechanism is intrinsic to MRSA strains and might play a role in bypassing the 
antibacterial effect of the lactam compared to MSSA strains. The data indicates that the 
MRSA strains are better at mutating to survive in the presence of lactam 88 than the 
MSSA strains.  
Cell survival for MSSA and resistant mutants was also studied, where the effects of the 
lactam 30 on cell growth were evaluated when cultured in the absence or presence of N-
methylthio β-lactam 30 over a 2 hour time frame. 31 It was found that the growth of 
MSSA and MRSA increased logarithmically in the absence of lactam 30, but in the 
presence of β-lactam 30, was immediately halted.  
 
Figure 2.11. N-methylthio β-lactam 30. 
 
Other biological studies were also performed on the mutant MRSA strains, including 
monitoring the phenotypic changes, gene sequencing and proteomic studies, to elucidate 
if the lactam had an effect on FAS processes as hypothesized previously. 
The fabH gene was sequenced by Dr. Lindsey Shaw’s research group and it was found 
that the MRSA mutant had no difference in the fabH sequence compared to the parental 
strain. Also, the lack of fabH-based mutations in β-lactam-resistant MRSA mutants 
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suggested that alteration within the protein is not readily tolerated in the amino acid 
sequence, which led to the hypothesis that the inhibition of FAS by these β-lactams may 
occur by alternative pathways.  
In conclusion the β-lactam 30 was shown to have widespread effects on fatty acid 
synthesis and cell proliferation in staphylococci.  
 
2.7. Conclusion. 
Recent published studies
 33,34,35,45 
have suggested that the addition of exogenous fatty 
acids to growth media can circumvent the growth inhibitory effects of FAS-targeting 
compounds on bacteria. In this study, experiments were undertaken to determine if the 
antibacterial activity of N-thiolated β-lactams can likewise be over-ridden by exogenous 
fatty acids. For this, the MIC values for one of the compounds, lactam 88, were 
determined, in the presence of oleic acid and Tween 80. These two fatty acid additives 
reportedly overcame the in vitro inhibitory growth effects of certain fatty acid 
biosynthesis inhibitors, and if this would hold true for the N-thiolated β-lactam, this could 
indicate severe limitations in the clinical use of the lactams as antibacterials. The highly 
deadly, USA-100, the clinical MRSA strain, was cultured in growth media containing the 
fatty acids Tween 80 and oleic acid. On analyzing it with BSA as controls and also 
vancomycin (a cell wall biosynthesis inhibitor), and triclosan (a FAS inhibitor), results 
have shown that MIC values of vancomycin remained unaffected by the supplementation 
of growth media with fatty acids, while in case of triclosan the MIC value increased 100-
fold and 500-fold in the presence of oleic acid and Tween 80, respectively. The MIC of 
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N-sec-butylthio β-lactam 88, just shows a two-fold increase in the presence of either fatty 
acid additives which indicates that the FabH-mediated inhibition of FAS by the lactams is 
only weakly circumvented by exogenous fatty acids and that they may offer other  
inhibitory effects on fatty acid biosynthesis. 
These newer results thus suggest the uniqueness of N-thiolated β-lactams among other β-
lactam antibacterial agents and bacterial FAS inhibitors. Thus, N-thiolated β-lactam 
showcases its potential for the treatment of deadly bacterial infections caused by MRSA 
or other pathogenic microbes. 
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CHAPTER 3: STUDIES ON THE STRUCTURE-ACTIVITY RELATIONSHIP OF 
HYDROPHILIC SUBSTITUENTS AT THE C3 CENTER OF N-THIOLATED  
β-LACTAMS. 
 
3.1 Introduction. 
N-Thiolated β-lactams as discussed in the earlier chapters is a novel class of β-lactam 
antibiotics that target the Staphylococcus species, including MRSA strains. Figure 3.1 
depicts the skeletal structure of this family of molecules.   
 
Figure 3.1. Structures of N-thiolated β-lactams used in this study. 
 
The last chapter discussed the mode of action of these antimicrobials. In this chapter, 
however, the effect of the C3 group will be studied, and investigations pertaining to 
structural requirements for biological activity will be made, by making the group more 
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polar. Addition of polar groups could be afforded only with synthesis of a 3-hydroxylated 
N-thiolated β-lactam, in which the OR group is substituted with a hydroxyl moiety. 
Figure 3.2 illustrates the structure of a 3-hydroxylated N-thiolated β-lactam. 
 
Figure 3.2. Structures of 3-hydroxylated N-thiolated β-lactams used in the study. 
 
It has been seen in various studies in our laboratory that the bioactivity of these N-
thiolated β-lactams is largely insensitive to changes in structure of the ring substituents at 
the C3 and C4 centers of the lactam ring, strongly suggesting that the compounds exert 
their antibacterial effects on a completely different cellular target and through a different 
mode of action than previously studied β-lactam antibacterials.1 As a follow-up study to 
Dr. Julio Garay’s Ph.D. work in our lab, which dealt with lengthening the lipophilic side 
chain at the C3 position of N-thiolated β-lactams, my work focused on attachment of 
hydrophilic side chains, like amino acid residues. The hypothesis was to enhance water-
solubility and bacterial cell targeting. But, before going into this, a brief discussion about 
cell transport, amino acids and carbohydrates will be presented.    
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3.2. Facilitated diffusion. 
The chemical structure and nature of the side chain residues attached to a pharmaceutical 
agent usually dictates its ability to cross cell membranes, whether it is a hydrophobic or 
hydrophilic drug and whether it is charged or uncharged. Lipid-soluble or hydrophobic 
drugs are readily soluble in the membrane bilayers and thus it is easier for them to move 
across the biological membranes.
2 
Water-soluble drugs on the other hand have a hard 
time getting through the membrane, and thus have to enter the cell through aqueous 
channels or pores in the membrane. Water-soluble drugs that must enter the bacterial cell 
for their biological function are thus expected to have a lower bacteriostatic activity, than 
those that can pass more readily through the membrane, while those compounds with 
excessive hydrophobicity may be secluded in the membrane or internal organelles, 
lowering the effective concentration in the cytoplasm. Polar molecules and charged 
ions usually enter the cell with the help of specific transmembrane integral proteins. The 
conformation of these carrier proteins, for example, permeases, changes to allow the 
drugs or endogenous molecules like glucose or amino acids to pass through the interior of 
cells, from an area of high concentration to an area of low concentration. This process of 
passive transport is known as facilitated diffusion 
3
, and is illustrated in Figure 3.3 below.  
The 3 Steps to Facilitated Diffusion are: 
1) Molecule outside the cell binds to carrier protein. 
2) Carrier protein changes shape and transports molecule across membrane. 
3) Molecule released inside the cell and protein returns back to original shape. 
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Figure 3.3. Facilitated diffusion through a membrane lipid bilayer. 
 
3.3. Amino acids. 
In humans, proteinaceous material makes up approximately 17 percent of the total body 
weight, and a variety of proteins differing in the structure and chemical properties can be 
formed when amino acids are arranged in varying sequence. Thus, the chemical 
properties of the amino acids directly or indirectly determine the biological activity of the 
protein. Proteins are made up of one or more polypeptide molecules.
4 
Polypeptides are chains of amino acids linked covalently through amide units created by 
peptide bonds. The general structure of α-amino acids consists of an amino terminal or N-
terminal, having a free amino group (NH2 or NH3+), adjacent to a carboxylic acid. The 
structure of the R moiety determines the identity and chemical properties of the amino 
acid, R-CH(NH2)-COOH. 
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There are thousands of amino acids occurring in nature. Of these, 20 are commonly found 
in proteins.  They can be classified based on acidity or basicity, polar side chains or 
nonpolar side chains, hydrophilicity (water-loving) or hydrophobicity (water-fearing) and 
optical activity. α-Amino acids are further classified into two groups: 5  
 Essential amino acids 
 Nonessential amino acids
 
 
The human body can synthesize almost half of the amino acids necessary to build 
proteins, except the essential amino acids. There are eleven nonessential amino acids, 
meaning that the body is capable of synthesizing them and nine essential amino acids that 
the body is unable to synthesize, and thus need to be supplied via diet.
6   
Glycine is the 
simplest amino acid, and lacks stereochemistry. 
Attaching an amino acid in our drugs is of great importance as lots of drugs have 
primary, secondary or tertiary amines as a part of their structure. This allows the drug to 
exist in two forms, a charged form, which dissolves readily in water, and an uncharged 
form, which can easily cross membranes, thus is of important biological significance. 
 
3.4.Carbohydrates. 
Carbohydrates are another important class of molecules involved in living organisms and 
are the most abundant of all biomolecules. Carbohydrates are also known as saccharides 
and the simplest carbohydrates are monocyclic and called monosaccharides. 
Monosaccharides can be linked together to form oligosaccharides and polysaccharides.
7 
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Cell walls of plants and bacteria contain insoluble sugars which function as structural 
materials and in the connective tissue and cell coats of animals. Living organisms break 
down complex carbohydrates into simple monosaccharides by digestion to provide 
energy. 
Figure 3.4 below illustrates the structure of three common monosaccharides, glucose, 
mannose and galactose. 
Mannose is a C-2 epimer of glucose. (D)-mannose is produced and occurs naturally in 
urinary tract lining cells and also used to cure urinary tract infections. It disrupts the 
adherence of bacteria in the urinary tract.
8, 9 
Galactose is also a simple sugar. Both glucose and galactose have the same molecular 
formula, but are C4 epimers. (D)-galactose is an important saccharide that our body needs 
and is a component of the immune system. These two sugars have been used in our 
synthesis and are discussed below.  
 
3.5.  Background. 
Extensive research has shown that the presence of an N-organothio group (N-S-R’) is 
pivotal for the activity of N-thiolated β-lactams, for this entity plays an important role in 
the compounds mechanism of action.
10
 Further, it was recently shown that structurally 
related N-alkylthio-2-oxazolidinones showcase the same trends 
11
, showing that the four-
membered β-lactam ring itself does not play any vital role in bioactivity. Figure 3.5 
below illustrates the structure of the N-alkylthio-2-oxazolidinone.
12
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Figure 3.4. Structure of (D)-glucose, (D)-mannose and (D)-galactose. 
 
Figure 3.5. Chemical structure of N-alkylthio-2-oxazolidinones. 
 
These prior studies show that groups at C3 and C4 center on the lactam ring play a subtle 
role in determining bioactivity. Thus, modification of the hydrophobicity or 
hydrophilicity of the C3 side chain of these lactams would be expected to influence the 
microbiological activity. The modifications could perhaps change the compound’s ability 
to pass through the cell wall and cellular membrane to reach the cytoplasm and interact 
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with intracellular targets. As discussed earlier, if a drug is too hydrophilic then it can be 
expected to be poorly absorbed as it is unable to cross the lipid-rich cell membrane, while 
hydrophobic drugs might be absorbed easily.
13
 In contrary, excessively lipid-soluble 
(hydrophobic) drugs are also poorly absorbed and cannot gain access to the surface of 
cells as they are totally insoluble in water, or may be sequestered in cellular membranes. 
For a drug to be readily absorbed the structural component of the drug should make it 
largely hydrophobic; yet it should have some solubility in water.
14 
This led to the study of 
the effect of side chain structure and polarity at the C3 position of N-thiolated β-lactams 
on the solubility and antibacterial activity starting with water-soluble polar groups like 
amino acids. This was followed by attaching small carbohydrates to the C3 center of N-
methylthio and N-sec-butylthio β-lactams. Figure 3.6 below shows two examples of 
glycosylated β-lactams. Below compounds and similar molecules have been synthesized 
previously in our lab by Dr. Sampath Abeylath. 
The other objective of these investigations was to see if there is a correlation between 
chain length and polarity at the C3 position of N-thiolated β-lactams on the antibacterial 
activity.  
 
Figure 3.6. Mannose-attached N-thiolated β-lactams. 
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3.6. Prior studies. 
Early experiments done previously by students in our laboratory have shown that 
increasing polar side chains at C3 of N-methylthio β-lactams were detrimental to 
antibacterial activity. However, the first set of compounds examined and screened for 
structure-activity relationships of C3 substituted analogs were polar amine-containing 
groups, prepared by Dr. Helen Wang as shown in Figure 3.7. 
Five 3-amino substituted lactams, 50-54, were tested for micro biological activities 
against MSSA and MRSA strains by Kirby-Bauer disk diffusion
1
. Results showed that 
only the N-benzyl substituted compound 52 had activity albeit weak, against MRSA. This 
suggested that amino substituents at C3 of these N-methylthio lactams significantly 
diminish anti-MRSA activity. 
 
 
Figure 3.7. C3-amino-substituted analogs 51-54 and azido-lactam 50. 
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Further, two new compounds bearing caprolactone side chains, lactams 103 a, b as 
illustrated in Scheme 3.1, were prepared by Dr. Michelle Leslie in our lab.
15, 16
  
The coupling reaction to form the ester was carried out using 1-ethyl-3-(3-
dimethylaminopropyl) carbodiimide) (EDCI or EDC) and 4-Dimethylaminopyridine 
(DMAP). EDCI is generally used as a coupling agent by activating the carboxyl group to 
couple with primary amines to yield amide bonds. Structure of EDCI and DMAP are 
shown below in Figure 3.8. Figure 3.9 demonstrates the lactam-lactone conjugates. 
 
Figure 3.8. Structure of EDCI and DMAP. 
 
The synthesis of lactams 103a, b was done by the coupling of caprolactone free acid with 
the hydroxyl β-lactams under EDCI and catalytic amount of DMAP as illustrated in 
Scheme 3.1. 
The values in Table 3.1 indicate the diameters in mm for the zone of growth inhibition 
induced by compounds 30, 88 and 103a, b after 24 hours of incubation at 37
o
C. The 
screening for bioactivity was carried out using the Kirby-Bauer method of disc or well 
diffusion. Twenty micrograms of each test compound in DMSO solution was used. All of 
the microbes listed were β−lactamase-producing strains of methicillin-resistant 
Staphylococcus aureus (MRSA). Those labeled as MRSA 652-659 were obtained from a 
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clinical testing laboratory at Lakeland Regional Medical Center, Lakeland, FL and 
MRSA 919 is ATCC 43300 purchased from American Type Culture Collections.
16
 
 
Scheme 3.1. Reaction conditions (a) 1.5 eq. EDCI, cat. DMAP, dry CH2Cl2, 12h, rt. 
 
 
Figure 3.9. Functionalized lactam-lactone conjugates. 
 
The new lactam-lactone conjugates 103 a, b, were screened for anti- MRSA activity and 
the results are shown below along with the zones of growth inhibition for the two 
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reference drugs, Penicillin G (PenG) and Vancomycin (Van). All experiments were 
performed in triplicate. 
Dr. Leslie’s results showed that the anti-MRSA activities of the β-lactams 103a and 103b 
appear to be less than the corresponding C3 hydroxy β-lactam analogs 30 and 88 from 
which they were prepared. Table 3.1, depicting the zones of inhibition also shows that the 
N-methylthio β-lactams 30 showed lower anti-MRSA activities than the N-sec-butylthio 
β-lactams 88. 
Next, Dr. Sampath Abeylath in our lab synthesized more hydrophilic glycosylated β-
lactams. The first lactam in this class was an acrylate monomer 102 illustrated in Figure 
3.10 containing two appended N-thiolated β-lactam units bound to a protected 
monosaccharide via short (succinate) linkers.
 17 
Lactam 102 was not miscible in the broth media and thus the MIC value of this 
compound was necessarily obtained by agar plate dilution. The compound was found to 
be largely inactive against Staphylococcus aureus and a strain of methicillin-resistant 
Staphylococcus aureus (MRSA), with MIC values of 128 µg/ml. 
C4- glycosylated β-Lactam 104 a-d illustrated in Figure 3.11 was synthesized by Dr. Ivan 
Perez Sanchez in our lab. These derivatives were derived from protected D-(+)-galactose, 
D-(-)-ribose and D-(+)-glucose, respectively, through a five-step sequence employed in 
the Julia–Lythgoe–Kocienski olefination with aldehydes.18 
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Table 3.1. Zones of growth inhibition for lactams 30, 88 and lactam-lactone 
conjugates 103 a, b against MRSA. 
Comp #  
MRSA 
652 
MRSA 
653 
MRSA 
654 
MRSA 
655 
MRSA 
656 
MRSA 
657 
MRSA 
658 
MRSA 
659 
MRSA 
919 
PenG 8 16 10 14 12 12 19 15 nd 
Van 16 15 16 16 21 15 15 15 nd 
30(R=Cl) 19 17 17 19 18 16 19 18 18 
88(R=Cl) 32 28 29 28 28 25 29 29 30 
103a 15 17 15 15 14 16 16 16 14 
103b 23 21 22 21 22 21 21 21 22 
 
These compounds were tested for antibacterial activity, and had MIC values of 32 to 64 
µg/mL against MRSA and MSSA. This strongly suggests that the placement of 
carbohydrate groups at either the C3 or C4 positions of N-thiolated β-lactams can have 
antibacterial activity, but their effects appear to be somewhat detrimental. Going in the 
opposite direction, towards more lipophilic side chains, β-lactam derivatives having fatty 
acyl substituents were also looked into by Dr. Julio Garay during his doctoral research in 
our lab. He prepared a wide selection of derivatives substituted with linear and branched 
acyl groups at C3 position of the β-lactam ring.
19 
For N-methylthio β-lactam analogs 
105a-o, illustrated in Figure 3.12, none exhibited higher antimicrobial activity than the 
parent β-lactam 30, which indicates that an increase in lipophilic character at the position 
C3 of the β-lactam ring does not improve the biological activity. 
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Figure 3.10. Carbohydrated β-lactam 102 having two appended N-thiolated β-
lactams. 
 
 
Figure 3.11. C4-Glycosylated β-lactams. 
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Similar results were seen for lactams 106a-m, depicted in Figure 3.13, where the 
organothio moiety was N-sec-butylthio. 
Thus, it could be generalized that for lipophilic β-lactam analogs, lower acyl chain length 
leads to better inhibitory activity. There appears to be limits to this, as the heptadecanoyl 
analogs 105l and 106j afforded no inhibitory activity.  
Results in Figure 3.12 shows that none of the N-methylthio β-lactam analogs showed 
higher antimicrobial activity when compared to parent β-lactam 60, which clearly 
indicates that the position at C3 of the β-lactam ring does not tolerate any increase in 
lipophilic character. 
 
 
Figure 3.12. Antibacterial activity of the N-methylthio β-lactam analogs substituted 
with different fatty acids at the C3 position of the β-lactam ring tested against 
MRSA ATCC 43300 as determined by the Kirby-Bauer assay. 
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Figure 3.13. Antibacterial activity of the N-Sec-butylthio β-lactam analogs 
substituted with different fatty acids at the C3 position of the β-lactam ring tested 
against MRSA ATCC 43300 as determined by the Kirby-Bauer assay. 
 
When N-sec-butylthio β-lactam were tested for antimicrobial activity, as for the case of 
N-methylthio β-lactam analogs as shown in Figure 3.14, none of the synthesized analogs 
showed any better antimicrobial activity. 
The MIC values (in μg/ml) shown above are against Staphylococcus aureus ATCC 
25923. The analysis was done in duplicate using mannitol agar with phenol red as 
indicator. MICs were better for the shorter length side chain analogs compared to the 
longer chain analogs. 
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Figure 3.14. C3-Fatty acyl N-methylthio and N-sec-butylthio β-lactam analogs and 
their MICs against S. aureus ATCC 25923.  
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3.7. Results & discussion. 
3.7.1 Reactions with amino acids. 
Hydroxy β-lactam 60*, 60a* was coupled using EDCI/DMAP with amino acids in an 
attempt to make C3-acylated β-lactams. The first trial was with glycine shown below in 
Scheme 3.2.  It was seen that the reaction did not work and the starting materials could 
not be recovered.   
 
Scheme 3.2. Attempted coupling of of C3-hydroxy β-lactam 60* with glycine. No 
product was isolated. 
 
It could be possible that the free amine in the amino acyl side chain adduct attacked the 
carbonyl carbon of the β-lactam ring and thus opened the lactam ring, destroying the β-
lactam core structure. Coupling of the lactam was then tried with Gly-Gly and Gly-Gly-
Gly-Gly-Gly, illustrated in Scheme 3.3 and Scheme 3.4, to increase steric hindrance in 
the chain such that the free amine is inaccessible to the carbonyl carbon of the β-lactam 
ring. These attempts were likewise unsuccessful.  
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Scheme 3.3. Attempted coupling of of C3-hydroxy β-lactam 60* with gly-gly. No 
product was isolated. 
 
 
Scheme 3.4.  Attempted coupling of C3-hydroxy β-lactam 60* with Gly-Gly-Gly-Gly-
Gly. No product was isolated. 
 
Following these failures, different carbamate groups like t-BOC (di-tert-butoxy carbonyl) 
and FMOC (fluorenylmethyloxycarbonyl) were used to N-protect a selection of amino 
acids prior to attachment to the attachment to the β-lactam ring. Scheme 3.5 and 3.6 
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below shows the coupling of t-BOC glycine with the hydroxy β-lactam 60* and hydroxy 
β-lactam 60a*.  
 
Scheme 3.5. Successful coupling of N-Boc glycine to C3-hydroxy β-lactam 60*. 
Scheme 3.6. Successful coupling of N-Boc glycine to C3-hydroxy β-lactam 60a*. 
 
Experimentally, the desired amino acid (1 equiv.), EDCI (1.1 equiv.), and DMAP (0.3 
equiv.) were dissolved in 10 ml methylene chloride and stirred in an ice bath for 10 
minutes. The N-thiolated β-lactam (1 equiv.) dissolved in 5 ml of methylene chloride was 
slowly added to the stirring mixture of amino acid. The resulting mixture was stirred at 
room temperature under argon for 12 hours. TLC was checked before quenching the 
reaction with water. The organic layer was separated, dried, and concentrated under 
vacuum. The resulting residue was separated by silica gel column chromatography. 
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A series of compounds, 107-116, shown in Figure 3.15, were then made using different 
amino acids having t-BOC or FMOC protecting groups, by the coupling reaction with the 
3-hydroxy β-lactam using EDCI/DMAP. 
Compounds 107-116 were prepared via the coupling reaction shown in Scheme 3.17. 
NMR spectra of compounds 107-116 are attached at the end of the chapter. To prepare 
the acyl side chains in lactams 114 and 115, 1,2-diaminoethane was reacted with di-tert-
butyl dicarbonate to give the mono-Boc-1,2-diaminoethane F in 77% yield. F was then 
reacted with succinic anhydride to yield the Boc-protected carbamic acid with 72% yield 
depicted in Scheme 3.7. 
 
Scheme 3.7. Preparation of N-BOC-protected carboxylic acid. 
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Figure 3.15. N-Thiolated β-lactams 107-116 containing t-BOC or FMOC protected 
amino acyl side chains. 
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Reaction of H with 3-hydroxy β-lactam 60* and 60a* by EDCI/DMAP coupling gave 
compounds 114 and 115, respectively (Scheme 3.8). Yield were 77% and 72% for 
compounds 114 and 115, respectively. 
  
Scheme 3.8. Acylation to make 114 and 115. 
 
These N-protected amino acyl lactams 107-116 were then tested for antimicrobial activity 
by measurement of Minimum Inhibitory Concentration (MIC) values in broth. These 
experiments were performed by Lacey Harrington in Dr. Lindsey Shaw’s laboratory 
(USF Department of Cell Biology, Microbiology and Molecular Biology).  
Table 3.2 shows the broth MIC value of the compounds against MRSA USA 100 635. 
The MIC’s for N-methylthio lactams 109, 111, 112, 113, 115 and 116 were above 
250µg/ml, indicating that none of them had any measurable antibacterial activity towards 
the test microbes.  
   
113 
 
Two N-sec-butylthio β-lactam analogs 107 and 114 were of particular interest to us, but 
lactam 107 was inactive while lactam 114 was active, with an MIC of 10 µg/ml.  This is 
in contrast with the N-methylthio analog 115, which had no activity. 
Control compounds with N-PMP 108 and N-benzyl 110 side chains on the β-lactam, 
were also found inactive, as we had expected them to be. 
Table 3.2. MIC values for N-protected amino acyl β-lactams 107-116 against S. 
aureus USA 100 635.  
Lactam 1μg/ml 10μg/ml 25μg/ml 50μg/ml 100μg/ml 
107 - - - - - 
108 - - - - - 
109 - - - - - 
110 - - - - - 
111 - - - - - 
112 - - - - - 
113 - - - - - 
114 - X X X X 
115 - - - - - 
116 - - - - - 
 
- Growth 
 
 
  
 
X No Growth     
 
These compounds were tested against S. aureus USA 100 635 and each MIC’s was 
performed in triplicate. 
Lactam 114 was further explored for bioactivity against other bacteria such as S. aureus 
USA 100 635, E. faecalis, B. anthracis and E. coli. Minimum Bactericidal Concentration 
(MBC) and Minimum Biofilm Eradication Concentration (MBEC) were also carried out 
for lactam 114. MBC tells us how good the compound is at killing the bacteria and 
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MBEC tells us how good it is at destroying biofilms.  Results for lactam 114 are shown 
below. Tables 3.3-3.6 highlight the Kirby-Bauer assay results of lactam 114 against S. 
aureus USA 100 635, E. faecalis, B. anthracis and E. coli strains. G signifies growth and 
X signifies no growth. 
a Growth 
X No Growth 
 
Table 3.3.  MIC values of lactam 114 against S. aureus USA 100 63.  
 Trial 1 Trial 2 Trial 3 
1μg/ml a a a 
2.5μg/ml a a a 
5μg/ml a a a 
7.5μg/ml a a a 
10μg/ml X X X 
15μg/ml X X X 
 
Table 3.4. MIC values of lactam 114 against E. faecalis.  
 Trial 1  Trial 2 Trial 3 
1μg/ml a a a 
10μg/ml a a X 
25μg/ml a a a 
50μg/ml a a a 
100μg/ml X X X 
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Table 3.5. MIC values of lactam 114 against B. anthracis.  
 Trial 1  Trial 2 Trial 3 
1μg/ml a a a 
2.5μg/ml a a a 
5μg/ml a a a 
7.5μg/ml a a a 
10μg/ml X X X 
 
Table 3.6. MIC values of lactam 114 against E. coli.  
 Trial 1  Trial 2 Trial 3 
1μg/ml a a a 
10μg/ml X X X 
25μg/ml a a a 
50μg/ml a a a 
100μg/ml X X X 
 
 
3.7.2. Antifungal Testing.  
Lacey Harrington in Dr. Lindsey Shaw’s laboratory (USF Department of Cell Biology, 
Microbiology and Molecular Biology) did the Kirby Bauer assay for lactam 114. Result 
showed no inhibition of growth of yeast. Dr. Andreas Seyfang’s laboratory (USF Health 
Department of College of Medicine-Molecular Medicine) did the antifungal testing of N-
protected amino acyl lactams against Candida albicans. 
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Candida albicans is a diploid fungus that is an opportunistic human pathogen, causing a 
wide variety of infections in immunocompromised patients. Hospital-acquired infections 
by Candida albicans have become a cause of major health concerns and could even lead 
to life-threatening systemic infections in humans. These are commensal and are present 
in the human mouth and gastrointestinal tract. Candidiasis or thrush is one of the most 
common fungal infections caused by Candida albicans.
24a, 24b
 
Drug assays involving the fungal species, Candida albicans were done. Compounds 107, 
108, 109, 110, 111, 115 and 116 were tested against the fungus with encouraging results. 
The cell density is found out using different drug concentrations using a OD600 
spectrophotometer. It is used in the analysis of cell density of cell components, proteins 
and nucleic acids mainly by measuring the turbidity produced during cell growth. The 
range for linearity for this instrument is up to 0.6 at 600 nm. For the assay, Candida 
cultures were incubated for 17, 18, and 19.5 h with the drugs before measuring the cell 
density as compared to the control wells without drug and with DMSO as solvent control. 
The final drug concentrations tested ranged from 8-128 µg/mL with 2 fold dilutions done 
on the 100 µl Candida cells. The results show that for 109, 110, 111, and 115 there is 
decrease in the cell density with increase in drug concentrations. And it is interesting to 
note that in the same class of compounds, there are some that do show fungal cell 
inhibition and some do not show any. Lactam 107 showed no inhibition with the IC50 
value above 10,000.  
The IC50 values were calculated using the Langmuir-Hill equation for pharmacological 
curve fitting of drug binding kinetics (using SigmaPlot),  
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The Langmuir-Hill equation
24c
 is shown below,  
                        αµ                                                             
        1   =     αµ + V1 
Where, α = Characteristic rate of diffusion towards a surface referred to as rate of 
condensation (Langmuir adsorption constant). 
V1= Characteristic rate of dissociation. 
µ = Concentration of the drug. 
1  = Surface area bound by molecule. 
Calculation of the slope and the intercept from the graph, gives α, V1 and 1. 
In summary, the strongest growth inhibitory effect found for those ten β-lactams against 
C. albicans is for lactam 115, with an IC50 of 10.3+/-7.4 µg/ml, followed by lactam 111 
with an IC50 of 29.3+/-1.7 µg/ml, and then by lactam 110 with IC50 of 304+/-104 µg/ml. 
 
3.7.3. Deprotection of the t-BOC and FMOC protecting groups. 
Deprotection of the t-BOC and FMOC protecting groups was attempted, as shown in 
Scheme 3.9 below. 
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Scheme 3.9. Hydrolysis of the t-BOC and FMOC groups with acid or base. 
 
For the deprotection of the t-BOC group, the reaction was carried out in acidic media 
using TFA in CH2Cl2 and for the deprotection of the FMOC group, the experiment used a 
basic media of piperidine/DMF in a 1:4 ratio with mild heating. However, neither 
condition yielded the desired amine product. Additionally, the β-lactam starting material 
was also not recovered. TLC showed new spots, a faint spot similar to hydroxylated β-
lactam but no starting material spot was visible. NMR confirmed the presence of 3-
hydroxy β-lactam after silica gel flash chromatography. LCMS also showed no presence 
of the desired free amine β-lactam but the presence of 3-hydroxy β-lactam was again 
confirmed. 
Thus, in conclusion, the lengthening of the side chain of the N-alkylthio β-lactams having 
amino acyl side chains at C3 did not improve the antibacterial properties.  
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In the next section similar studies are described for derivatives having more polar 
moieties at C3. 
 
3.7.4.  Reactions with carbohydrates.   
In the previous section we studied the attachment of amino acids to N-alkylthio β-lactams 
to make polar side chains, this section we will look into more polar groups in the form of 
glycosylated N-alkylthio β-lactams. Previously, Dr. Sampath Abeylath and Dr. Ivan 
Perez Sanchez have worked with various sugar-bearing N-alkylthio β-lactam derivatives 
and concluded that they do not enhance antimicrobial activity. Thus, Dr. Julio Garay 
studied fatty esters and concluded that lengthening the lipophilic chain is detrimental for 
antimicrobial activity. This also held true after we studied amino acids attached β-
lactams, we wanted to reconfirm our hypothesis using carbohydrates, which too are polar 
compounds were studied and this section will discuss these studies. 
Ether linkages was first tried before ester linkages but without success. 
1,2:3,4-Di-O-isopropylidene-D-galactopyranose was reacted with tosyl chloride to 
protect the alcohol, and then reaction with lactam 60* in presence of a base like 
triethylamine or sodium hydride. However, this did not yield the desired product. 
Compounds 117-121 were synthesized as illustrated in Figure 3.17 below, and the effects 
of side chain hydrophilicity on antibacterial activity was evaluated. 
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Figure 3.16. Attempt to make ether linked glycosylated N-thiolated β-lactam. 
 
3.7.5. Preparation of Compounds 117 and 119.  
 
It was necessary to synthesize the requisite acetonide-containing acyl side chain of 
compounds 117 and 119 by refluxing solketal with succinic anhydride in the presence of 
triethylamine, as shown in Scheme 3.10. The yield of this acylation was 65%. 
 
Scheme 3.10. Synthesis of G. 
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Figure 3.17. C3 Acylated β-lactams 117-121. 
 
Coupling of G with lactam 60* in presence of EDCI and a catalytic amount of DMAP 
gave lactam 117 in 66% yield. 
 
Scheme 3.11. Coupling of acid G to lactam 60*. 
   
122 
 
Acetonide deprotection of lactams 117 was done using NaHSiO4SiO2 at room 
temperature to yield compound 118 in 52% yield as shown in scheme 3.12. The same 
procedure was done to prepare analogs 119 and 120.  
 
 
Scheme 3.12. Acetonide deprotection of lactams 117 to 118. 
 
3.7.6. Microbiological Testing of Lactams 117-121.  
Microbiological tests were done on these lactams as discussed in the previous section for 
the amino acyl lactams. These experiments were performed by Lacey Harrington in Dr. 
Lindsey Shaw’s laboratory (USF Department of Cell Biology, Microbiology and 
Molecular Biology). 
Table 3.7 shows the MIC values of the compounds against S. aureus strain USA 100 635, 
all the tests were done in triplicate. Results showed that all lactams in this group were 
found to be inactive.  
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Table 3.7. MIC values for compounds 117-121 against S. aureus USA 100 635.  
Lactam 1μg/ml 10μg/ml 25μg/ml 50μg/ml 100μg/ml 
117 G G G G G 
118 G G G G G 
119 G G G G G 
120 G G G G G 
121 G G G G G 
  
 
G Growth     
    X No Growth   
 
 
3.8. Reactions with polyethylene glycol (PEG). 
In follow-up to these investigations on highly oxygenated acyl side chain derivatives, 
another moiety targeted was polyethylene glycol, to synthesize “PEGylated” lactams. 
Polyethylene glycol (PEG) is a flexible and water-soluble polymer, and when attached to 
various groups, allows a slowed clearance of the carried group from the blood, which in 
turn achieves a longer acting medicinal effect and reduced toxicity, with longer dosing 
intervals
25,26
 PEGs are also found to be degraded by various bacteria, both in the presence
 
and the absence of oxygen.
27, 28, 29
 
Different reaction mechanisms are
 
said to be involved in PEG degradation, and it is 
generally accepted that
 
they all involve the formation of a labile intermediary hemiacetal
 
structure R-CH(OR')(OH). 
30 
PEG always has a free hydroxyl group present at the terminal -O-CH2-CH2-OH unit on 
the carbon vicinal to the ether linked carbon. Due to this situation, Acinetobacter species 
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effectively degrades PEG by continuous removal of ethylene glycol units from the PEG 
terminal shown below.
31
 
 
Figure 3.18. The vinyl-ether hydrolysis mechanism proposed by Pearce and 
Heydeman. 
 
It has been reported that high-molecular weight PEG, e.g., PEG 8000, is a strikingly 
potent dietary preventive agent against colorectal cancer in animal models.
32
 We thought 
it would be interesting to examine if a high-molecular weight PEG could be attached to 
our N-methylthio -lactam as a means to improve water solubility and possibly 
bioactivity. Given below, in Figure 3.19, is a core structure of a C3-pegylated -lactam, 
where “n” is 3 to 10.  
 
 
Figure 3.19. C3-pegylated -lactam derivatives. 
 
Attempts were made to append PEG (MW 300) to hydroxyl lactam 60* via acylation 
through a succinate ester, such as shown in Scheme 3.13. 
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Experiments to couple succinic acid to the hydroxy lactam 60* using either EDCI/DMAP 
or Ph3P/DEAD failed to give the desired acylated product 122 (Scheme 3.13). Also, 
experiments involving γ-butyrolactone and hydroxy lactam 60* using NaH and DCM 
failed to give product 123 (Scheme 3.14). 
 
Scheme 3.13. Attempts to attach a succinyl linker to 3-hydroxy-β-lactam 60*. 
 
 
Scheme 3.14. Attempt to react γ-butyrolactone and hydroxy lactam 60*. 
 
Alternatively, Scheme 3.15 was tried using 1,1'-carbonyldiimidazole (CDI), as a means to 
append an ethylene glycol side chain to C3 of lactam 124. Most of the starting material 
was recovered. 
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Scheme 3.15. Attempt to attach ethylene glycol. 
 
3.9. Experimental Studies.  
All reagents and solvents were purchased from Sigma-Aldrich Company or Fisher 
Scientific and used without further purification unless otherwise stated.  Products were 
purified by flash column chromatography with J. T. Baker flash chromatography silica 
gel (200-400 mesh). NMR spectra were recorded in CDCl3.  
 
3.9.1. Synthesis of C3-Substituted β-lactam analogs. 
The synthetic pathway to prepare the C3 acyl substituted β-lactam analogs is depicted in 
Scheme 3.16. It is similar to the reaction pathway shown in Chapter 2, and involves a five 
stage sequence of reactions initiated by the synthesis of N-(4-methoxyphenyl) imine B 
from benzaldehyde A and p-anisidine. Acetoxyacetyl chloride and imine B are coupled 
together by a Staudinger reaction to provide exclusively the cis-substituted β-lactam C as 
a racemic mixture, followed by oxidative cleavage of the p-anisyl moiety by ceric 
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ammonium nitrate to yield the N-thiolated β-lactam D.  This is then followed by reaction 
with either N-(methylthio) phthalimide or N-(sec-butylthio) phthalimide to yield the N-
thiolated β-lactam E. The last step in this sequence is the hydrolysis of the acetoxy group 
under basic conditions to afford the C3-hydroxy compound 60* as the starting material 
for further chemical transformations. The steps are discussed in details in the following 
section.
20
 
 
Scheme 3.16. General synthetic pathway to prepare the β-lactam 60*.  
 
Following this synthesis, due to the presence of the alcohol moiety on 60* various esters 
were synthesized by activation of the respective N-protected amino acid with 1-ethyl-3-
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(3-dimethylaminopropyl) carbodiimide hydrochloride (EDCI), and 4-
dimethylaminopyridine (DMAP) in dry dichloromethane, as is shown in Scheme 3.17. O-
chlorophenyl series were synthesized from different intermediates from Turos lab. 
 
 
Scheme 3.17. Synthesis of C3-esterified β-lactam analogs.  
 
3.9.2. Details of synthetic procedure. 
3.9.2.1.  Step a : Synthesis of N-(4-methoxyphenyl) imine B. 
To a solution of p-anisidine (7.27 g, 59.0 mmol), 50 mL CH2Cl2 and   benzaldehyde (5.00 
g, 47.2 mmol) were added, along with a catalytic amount of camphorsulfonic acid 
(depicted in Scheme 3.18).
21
  
 
Scheme 3.18. Synthesis of N-(4-methoxyphenyl) imine B. 
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The resultant mixture was stirred until TLC indicated the disappearance of starting 
materials. The solvent was removed under reduced pressure, and the crude material was 
purified by recrystallization from ice-cold MeOH to give imine B as a white solid in 85% 
yield. (M.P. 58–60 oC) 
 
1
H NMR (250 MHz, CDCl3) spectra : δ 8.42 (1H, s), 7.85–7.82 (2H, m),7.40 (3H, t, J = 
3.2 Hz), 7.20–7.15 (2H, m), 6.87 (2H,dd, J = 2.0, 7.8 Hz), 3.77 (3H, s); 13C NMR (63 
MHz,CDCl3): δ 156.5, 155.2, 144.2, 132.2.7, 130.3, 128.7, 122.9, 122.4, 114.8, 114.3, 
55.9.  
3.9.2.2. Step b: Staudinger coupling of acetoxyacetyl chloride with imine B. 
Imine B (17.3 g, 70.4 mmol) was dissolved in 200 mL of freshly distilled CH2Cl2. The 
solution was cooled to approximately 5 
o
C in an ice bath. Triethylamine (3 equiv, 21.4 g, 
211 mmol) was added, followed by acetoxyacetyl chloride (1.2 equiv, 11.5 g, 84.4 mmol) 
dissolved in 20 mL CH2Cl2, as illustrated in Scheme 3.19. 
 
Scheme 3.19. Synthesis of N-4-methoxyphenyl azetidin-2-one. 
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The reaction mixture was stirred for 1 hour until no further change in TLC was observed. 
The solvent was removed under reduced pressure and the crude material was purified by 
washing with ice-cold MeOH. The product C was isolated in 56% yield as a white solid, 
m.p. 138–140 oC.  
1
H NMR (250 MHz, CDCl3): δ 7.32–7.20 (7H, m), 6.73 (2H, d, J = 8.9 Hz), 5.87 (1H, d, 
J = 4.8 Hz), 5.27 (1H, d, J = 5.0 Hz), 3.89 (3H, s), 1.60 (3H, s); 
13
C NMR (63 MHz, 
CDCl3): δ 168.6, 158.1, 142.6, 133.8, 130.1,129.9, 129.7, 128.6, 126.7, 118.5, 114.9, 
114.4, 75.4,58.1, 55.3, 19.8. 
3.9.2.3. Step c :  N-Dearylation of N-(4-methoxyphenyl) azetidin-2-one.
22
 
 
Scheme 3.20. N-Dearylation of N-(4-methoxyphenyl) azetidin-2-one C. 
 
A solution of N-4-methoxyphenyl azetidin-2-one C (8.0 g, 26mmol) in 240 ml of 
acetonitrile was cooled to 0
o
C and treated over a period of 60 minutes with an aqueous 
solution (72 ml) of ceric ammonium nitrate (CAN) (3 equiv, 42.0 g, 76.6 mmol).The 
solution was further stirred at 0
o
C for another 30 minutes before 250 ml of ethyl acetate 
was added. The aqueous layer was removed and extracted with two 100 ml of ethyl 
acetate. The combined organic layers were washed with 50 ml of saturated sodium 
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bicarbonate and three times with 50 ml portions of 10% sodium bisulfite. The organic 
layer was dried with brine (25 ml) and then further dehydrated with anhydrous sodium 
sulfate. The filtered solution was concentrated and then triturated with diethyl ether to 
give β-lactam D 3.65g (69%) as light orange oil, as shown in Scheme 3.20. 
1
H NMR (CDCl3): δ 7.36-7.29 (5H, m), 6.14 (1H, bs), 5.87 (1H, m), 5.03 (1H, d, J=4.4 
Hz), 1.66 (3H, s). 
3.9.2.4. Step d: Synthesis of N-thiolated azetidin-2-one E.
 
 
Synthesis of the sulfur-transfer reagents
23
: Two reagents were used for this study: N-
(methylthio)phthalimide and N-(sec-butylthio)phthalimide. Their syntheses are shown 
below in Scheme 3.21. 
 
Scheme 3.21. Synthesis of N-thiolated azetidin-2-one. 
 
3.9.2.5. Preparation of N-(methylthio)phthalimide.
23
 
An oven-dried round-bottom equipped with a pressure-equalizing dropping funnel was 
charged with 30 ml of pyridine, 38 ml of acetonitrile, phthalimide (6.0 g, 40.8 mmol), 
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and methyl disulfide (3.7 ml, 42 mmol). The suspension was stirred at room temperature 
for 20 minutes and then cooled to 0
o
C. Bromine (2.5 ml, 49 mmol) was added as a 30 ml 
acetonitrile solution over a period of 1.5 hours. The resulting suspended solution was 
stirred for 1 hour at 0
o
C and then water (150 ml) was added over a period of 45 minutes. 
Stirring was stopped and precipitate was allowed to settle for 1 hour. Filtration of the 
mixture gave 4.6 g (58%) of the product as a pale yellow solid, mp 175
o
C. 
1
H NMR (CDCl3) spectra: δ 7.95 (4H, m), 2.57 (3H, s). 
3.9.2.6. Preparation of (±)-(3R,4S)-3-acetoxy-N-methylthio-azetidin-2-one. 
A suspension of β-lactam D (2.50 g, 12.2 mmol), N-(methylthio) phthalimide (2.59 g, 
13.4 mmol) and 2 equivalents of Hunig’s base (4.0 ml, 24.2 mmol) in benzene (40 ml) 
was heated overnight at 70
o
C. The heat was removed and the mixture was allowed to 
stand overnight. The solution was concentrated over silica gel. Chromatography gave 
2.18 g (71%) of the product as a dirty yellow solid, mp 130–132oC.  
(±)-(3R,4S)-3-Acetoxy-N-methylthio-azetidin-2-one(E) : 
1
H NMR (250 MHz, CDCl3): δ 
7.30-7.34 (3H, m), 7.26-7.28 (2H, m), 5.89 (1H, d, J= 5.2 Hz), 4.99 (1H, d, J= 4.9 
Hz),2.42 (3H, s). 
3.9.2.7. Step e : Preparation of 3-hydroxylated N-thiolated β-lactams 60* 
Hydroxylation E takes using KOH/MeOH soulution as shown in Scheme 3.22 below. 
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Scheme 3.22. Hydrolysis of C3-acetoxy β-lactam E.  
 
3.9.2.8. Preparation of (±)-(3R,4S)-3-hydroxy-N-methylthio-azetidin-2-one 60* 
1.0 g (3.2 mmol) of compound E was dissolved in 5 ml of acetone and was placed in a 
round bottom flask with continuous stirring in an ice bath for 10 mins followed by 
addition of 0.36 g (6.4 mmol) of KOH dissolved in 10 ml of methanol was added. After 
15-20 min, the reaction mixture was quenched with 5 ml of water after checking the 
course of the reaction using the TLC. The solution was then extracted with ethyl acetate 
(3 x 15 ml). The organic fractions were combined and dried over anhydrous Na2SO4, the 
solution was filtered and evaporated reduced pressure. This compound was purified by 
flash chromatography using hexanes : ethyl acetate (2 : 1 ratio). The final product 60* 
was an orange oil obtained in 80% yield (0.79 mg). 
 
1
H NMR (400 MHz, CDCl3): δ 7.43-7.39 (3H, m), 7.30-7.25 (2H, m), 5.14 (1H, d, J= 5.2 
Hz), 4.93 (1H, d, J= 5.2 Hz), 2.42 (3H, s). 
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3.9.2.9. (±)-(3R,4S)3-hydroxy-N-sec-butylthioazetidin-2-one (60a*).  
White solid, 59 % yield. 
1
H NMR (400 MHz, CDCl3): δ 7.43-7.34 (3H, m), 7.25-7.20 
(2H, m), 5.21 (1H, d, J= 6.2 Hz), 4.90 (1H, d, J= 5.8 Hz), 2.96-2.90 (1H, m) 2.80-2.77 
(1H, m), 1.65-1.40 (3H, m), 1.26 (4H, dd, J= 6.8, 7.0 Hz), 0.93 (3H, m). 
The general procedure used to synthesize C3-acylated β-lactam analogs is shown in 
Scheme 3.23.  
 
Scheme 3.23. Synthesis of C3-acylated β-lactams. 
 
10 mg (0.04 mmol) of β-lactam 60* and 10 mg (0.052 mmol) of EDCI was dissolved in 5 
ml of freshly distilled CH2Cl2 placed in a round bottom flask. The solution was stirred in 
an ice bath for 15 min, and then 1.1 equiv of the respective carboxylic acids was added 
following by a catalytic amount of DMAP. The reaction progress was followed by TLC 
before quenching. The reaction mixture was washed with 2 ml of 5% KOH solution 
followed by extraction with CH2Cl2 (3 x 5 ml). The organic fractions were mixed and 
dried over anhydrous Na2SO4, filtered, and evaporated under vacuum.  The resulting 
product was purified by recrystallization in methanol.  
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3.10. Conclusion 
Amino acylated β-lactams 107-116 and carbohydrated β-lactams 117-121 were 
successfully synthesized at the C3 ring position. The amino acids had to be N-protected 
via t-BOC or FMOC groups to achieve the desired coupling. Following the successful 
synthesis, these compounds were tested using MIC determinations against various strains 
of antimicrobials. Unfortunately, the antibacterial activity of these compounds against S. 
aureus USA 100 635 did not improve. 
Neither structural features nor lengthening of the side chain of the amino acid side chains 
or carbohydrate groups substantially affected the antibacterial activity; rather, for most of 
the cases, it was detrimental. Further, antifungal testing on these compounds resulted in 
highest inhibitory activity, with an IC50 of 10.3+/-7.4 µg/ml, for lactam 115.  
The synthesis of “PEGylated” lactams was also attempted with no success. A new 
method to attach PEG to the lactams needs to be looked at and to make sure PEG being 
bought must have uniform “n” values for the mol. wt.  
Overall, as described earlier, lengthening of the lipophilic side chain resulted in the 
antibacterial activity being diminished, regardless of whether the chain contains 
unsaturation or branching.  From these studies and those previous, it is now confirmed 
that increasing chain length or polarity at the C3 position decreases antibacterial activity. 
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CHAPTER 4: DUAL-ACTION N-THIOLATED β-LACTAM 
 
4.1 Introduction. 
Bacterial resistance to antibiotics, in a short span of time, is becoming an increasing 
concern in the field of medicine, and the search for new drugs and alternate solutions to 
this problem is on. But even with extensive research, replacing antibiotics is still not a 
viable option considering the wide array of bacterial infections antibiotics can control. 
But overuse of antibiotics, has led to this situation and is a major global concern. The 
Centers for Disease Control and Prevention (CDC) is working to create global awareness 
and understanding of the subject. The previous chapters have outlined the mechanism of 
action and also structural modifications leading to changes in bioactivity for the new 
class of antibacterials, N-thiolated β-lactams. This chapter will investigate the synthesis 
of novel Ciprofloxacin-β-lactam dual-action drugs and their antimicrobial activity against 
various strains of bacteria, as an alternate solution to the bacterial resistance problem.  
Dual-action drugs, also known as “hybrids” or “combination drugs”, consist of a single 
compound that is a combination of two drugs with different pharmacological actions at a 
similar efficacious dose. Dual-action drugs have the ability to deliver two agents 
simultaneously, with each drug having a potential effect on a different or same target. In 
most cases, the active site of the drugs, also known as “pharmacophores”, have different 
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modes of action, which make the drug less resistant. The strategy of dual-action prodrugs 
and dual-action (or hybrid) drugs is to decrease the threat to bacterial resistance by 
blocking “a major bacterial resistance mechanism at the same time as interfering with 
another bacterial pathway or target site.” 2,3 This new variety of drug is expected to be 
more potent, active and show less drug resistance.
1
 
In an era of "superbugs", such as methicillin-resistant Staphylococcus aureas (MRSA), 
and an increasing public awareness and concern over bacterial infections, this type of 
drug design may reduce the severity and prevalence of drug-resistant infections. The 
overall expected process by which a dual-action drug might work is depicted in Scheme 
4.1. 
 
Drug A Drug B
Bacteria
Drug A + Drug B
Target A Target B Cell Death+  
Scheme 4.1. Scheme showing how a dual-action drug might work. 
 
Various studies showed that for the synthesis of the hybrid drugs, the linkage between the 
drugs does not necessarily have to be an ester linkage, and an amide linker might also be 
used.
5
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An example of this interesting class of drugs is the hybrid drugs synthesized by Peyton 
et.al. also known as reversed chloroquines, by combining the drug chloroquine with a 
reversal agent, which counters resistance and is based on the antidepressant imipramine, 
and was found to be around 10 times more potent than chloroquine itself.
4
 Here the 
hybrid drug is attached via an amine linker. 
 
Figure 4.1. Reversed chloroquines. 
 
4.2. Previous work on dual-action drugs. 
Cephalosporin, a class of β-lactam antibiotics, is more resistant to attack by β-lactamases 
as a result of certain substituents placed off the bicyclic ring.  Figure 4.2 below depicts 
the basic structure of a cephalosporin antibiotic and the new molecule (MCO) that was 
synthesized. 
Substitution of the N-acyl R group with N-mandeloyl, and the R’ with 2-
mercaptopyridine-N-oxide (also known as omadine), gives (6R,7R)-7-[(2R)-2-hydroxy-
2-phenylacetamido]-3-(pyrid-2-yl-N-oxide)thiomethylceph-3-em-4-carboxylic acid (also 
known as MCO). 
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Figure 4.2. Structure of a Cephalosporin and MCO. 
 
In 1976, O'Callaghan et. al. reported that unlike cephalosporin, MCO did not lose its 
antibacterial activity but rather in some cases showed enhanced activity when it was 
hydrolyzed by β-lactamase.6  
In a study in 1996, Ronald N. Jones and Martha Sanchez reported a tertiary amine-linked 
dual-action drug combination of a catechol cephalosporin and ciprofloxacin, Ro 25-0534 
shown in Figure 4.3. Ro 25-0534 was synthesized to enhance antipseudomonal activity 
and was shown to be comparatively less potent than ciprofloxacin against Gram-positive 
species.
7
  
Microbiotix, Inc. in 2007 used the term “hybrid”, for their anilinouracil-fluoroquinolone 
compound shown in Figure 4.4, which could potentially target two distinct steps in DNA 
replication.
8
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Figure 4.3. Structures of Ciprofloxacin and Ro 25-0534. 
 
 
Figure 4.4. Anilinouracil-fluoroquinolone. 
 
Daniel Long and Daniel Marquess published a review on patents submitted on novel 
heterodimer antibiotics containing various structures including either Ciprofloxacin or 
other antibiotics. The dual drug consists of two antibacterials from different classes of 
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antibiotics covalently bonded to each other. The review highlights various hybrid drugs 
and some emerging strategies based on a multivalent approach in drug discovery.
9
  
With the above mentioned benefits associated with dual drugs, synthesis of N-acyl 
Ciprofloxacin and N-thiolated β-lactam hybrids was attempted in our lab. Six analogs 
were isolated. Both Ciprofloxacin and N-thiolated β-lactam fall under different categories 
of antibiotics and have different modes of action to inhibit bacteria. 
 
4.3. Ciprofloxacin. 
Ciprofloxacin, an antibiotic belonging to the group of drugs called fluoroquinolones, is 
used to treat different infections including anthrax. Ciprofloxacin inhibits DNA gyrase, 
an enzyme that is an essential component in the mechanism that passes genetic 
information to daughter cells when a bacterial cell divides.
10
  
The ciprofloxacin antimicrobial is a broad spectrum antibiotic, but lacks potency against 
some streptococci, enterococci, and anaerobic bacteria.
11
 In 2009,  Azema et al. reported 
the use of several N-acyl ciprofloxacins as antitumor agents. Ciprofloxacin has been 
found to be active against the following microbes.  
Aerobic gram-positive microorganisms: Enterococcus faecalis (Many strains are only 
moderately susceptible.), Staphylococcus aureus (MRSA only), Staphylococcus 
epidermidis, Staphylococcus saprophyticus, Streptococcus pneumoniae (penicillin-
susceptible strains only),Streptococcus pyogenes. 
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Aerobic gram-negative microorganisms: Campylobacter jejuni, Proteus mirabilis, 
Citrobacter diversus, Proteus vulgaris, Citrobacter freundii, Providencia rettgeri, 
Enterobacter cloacae, Providencia stuartii, Escherichia coli, Pseudomonas aeruginosa, 
Haemophilus influenza, Salmonella typhi, Haemophilus parainfluenzae, Serratia 
marcescens, Klebsiella pneumoniae, Shigella boydii, Moraxella catarrhalis, Shigella 
dysenteriae, Morganella morganii,  Shigella flexneri, Neisseria gonorrhoeae, Shigella 
sonnei 
12
 
Bayer A.G. patented Ciprofloxacin in 1983 and subsequently the U.S. Food and Drug 
Administration (FDA) approved its use in 1987. Though ciprofloxacin has 12 FDA-
approved human uses and other veterinary uses, it is also used for unapproved off-label 
uses. Ciprofloxacin is known to interact with other drugs, herbal and natural supplements, 
like other antibacterial drugs such as amoxicillin, trimethoprim, azithromycin, 
cephalexin, and doxycycline. Ciprofloxacin is marketed as Baycip, Ciloxan, Ciflox, 
Cipro, Cipro XR, Cipro XL, Ciproxin, Prociflor, and most recently, Proquin.
13
  
Ciprofloxacin is sold in the market with the brand name CIPRO in the form of 
ciprofloxacin hydrochloride solid dosage form other than a 5% oral suspension in (5 g 
ciprofloxacin in 100 mL) and a 10% (10 g ciprofloxacin in 100 mL) suspension.
12
 
Ciprofloxacin hydrochloride is a yellowish solid with a molecular weight of 385.8. The 
structure of ciprofloxacin hydrochloride is given in Figure 4.5. 
 
Figure 4.5. Structure of ciprofloxacin hydrochlor 
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4.4. Reactivity of ciprofloxacin. 
Ciprofloxacin is generally a stable molecule but has been shown to decompose 
photochemically in aqueous solutions at an acidic pH as shown in Scheme 4.2.
14
  
 
Scheme 4.2. Photochemical decomposition of Ciprofloxacin. 
 
Several research studies and structure activity relationship (SAR) studies on quinolones 
have revealed that functional group attachment on the piperazine ring at C-7 position 
impacts antibacterial potency, the spectrum of activity, solubility and 
pharmacokinetics.
15,16,17
 It is the C-7 position that has been extensively used in the 
synthesis of the dual drugs where the drugs are linked to the C-7 terminus of the 
quinolone leaving the carboxylic acid end free. Figure 4.6 shows structural features and 
common pharmacophores of quinolone antibacterials. 
   
148 
 
 
Figure 4.6. Structural features and common pharmacophores on quinolone 
antibacterials. 
 
To further study the structure-activity trends of the quinolone antibacterials, synthesis of 
N-substituted piperazinyl quinolones was carried out by making either ester or amide 
linkages, via the carboxylic acid group. Haroon et al. showed how to conveniently 
synthesize some derivatives of ciprofloxacin through ester aminolysis. A structural 
scheme of synthesizing the amide linkage at the carboxyl end of the ciprofloxacin is 
shown below in Scheme 4.3.
18
 In the reaction, refluxing the ciprofloxacin derivative in 
methanol and sulfuric acid for 7-8 hours affords the ester intermediates, which on further 
refluxing with aniline yields the amide analog of ciprofloxacin. 
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Scheme 4.3. Synthesizing amide linker of ciprofloxacin. 
 
4.5. N-Acyl Ciprofloxacins. 
Dr. Ryan Cormier during his Ph.D. work in the Turos lab focused on synthesizing and 
studying the mode of action of N-acyl Ciprofloxacin analogs.
 19
 He also showed that 
antibacterial activity could be influenced by changing lipophilicity of the N-acyl residue.  
 
Figure 4.7. N-acyl ciprofloxacin (Dr. Ryan Cormier, Ph.D. thesis). 
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N-acyl ciprofloxacins were synthesized by treating a suspension of ciprofloxacin HCl salt 
(1 eq) and triethylamine (3 eq) in dichloromethane with the requisite acid anhydrides (1.2 
eq). Figure 4.8 to afford the required analog.  
The N-acyl ciprofloxacin analogs have better solubility in organic solvents as compared 
to ciprofloxacin and are found to have less resistance to MRSA as compared to 
ciprofloxacin. Moreover, there was no change in the mode of action of the N-acyl 
ciprofloxacins when compared to ciprofloxacin, whose mechanism of action is the 
interference of DNA synthesis.
19, 20
 In the present studies, a few of these N-acyl 
ciprofloxacin derivatives were re-synthesized, and an attempt was made to attach the N-
thiolated β-lactam to the C3 side chains of ciprofloxacin via different types of cleavable 
linkers. 
 
4.5.1. Synthesis of N-acyl ciprofloxacins. 
 
Figure 4.8. Acylation of Ciprofloxacin. 
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N-acyl ciprofloxacins were synthesized using corresponding acid anhydrides instead of 
acid chlorides as it resulted in a very small amount of N-acyl ciprofloxacin dimer (Figure 
4.9.). 
 
Figure 4.9. N-acyl ciprofloxacin dimer. 
 
4.5.2. Synthesis of N-acyl ciprofloxacin-β-lactam dual-action drugs. 
Scheme 3.2 was used to synthesize 3-hydroxy β-lactam 60a. Coupling of the lactam with 
the N-acyl ciprofloxacin using EDCI/DMAP in dichloromethane yielded the desired 
coupled product. (Scheme 4.4) 
 
Scheme 4.4. Coupling reaction of N-acyl ciprofloxacin with 3-hydroxy β-lactam 
60a*. 
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Reaction conditions were optimized to get the best results, owing to the limited reactivity 
of the C-3 carboxylic acid of the ciprofloxacin and C-3 secondary alcohol of N-thiolated 
β-lactam. Other coupling reagents were tried but without much success. Finally, the 
EDCI/DMAP coupling worked best when the N-thiolated β-lactam (dissolved in 
dichloromethane) was added to a stirred mixture of the N-acyl ciprofloxacin in 
dichloromethane under chilled reaction conditions. The reaction mixture was slowly 
brought to room temperature with continuous stirring. Completion of the reaction was 
checked using TLC, and then the solution was concentrated under vacuum. All reactions 
require 24 or more hours to yield desired products. Six N-acyl ciprofloxacin-N-thiolated 
β-lactam derivatives were synthesized as per this scheme, as shown in Figure 4.14. 
To explore the carboxylic acid side chain of the N-acyl ciprofloxacin, coupling with C3-
hydroxylated N-thiolated β-lactams 60, 60a the ester linkages were used rather than the 
already exhausted use of the amine side chain. Esters are easily cleavable inside the cell, 
so that the carboxylic side chain of the N-acyl ciprofloxacin could then be free to bind to 
the DNA gyrase complex. 
As previously known, the activity of N-thiolated β-lactams comes from the presence of 
the organothio moiety in the structure, thus, several analogs were made using N-
methylthio β-lactam and N-sec-butylthio β-lactam. One compound 128 was synthesized 
with a p-methoxyphenyl group as a control because we presume it would not show any 
synergistic activity from the N-thiolated β-lactam portion but only from the 
hydrolytically-released ciprofloxacin.  
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4.5.3. Purification and characterization of N-acyl Ciprofloxacin-β-lactam dual-
action prodrugs. 
Column chromatography was first used to purify the acylation products, but it was found 
that this alone did not give the pure compounds. Waters Prep-LC instrument with Agilent 
Eclipse XDB-C18 column was then used to extract the pure compound from the crude 
mixture. Inside Agilent Eclipse XDB-C18, an ultra-high pure silicon dioxide (SiO2), 
Zorbax Rx-SIL porous silica support was chemically bonded to a dense monolayer of 
dimethyl-n-octadecylsilane stationary phase. Water and acetonitrile (MeCN) with 0.05% 
TFA was used as a solvent system for mobile phase. Product purification was confirmed 
using LC-MS and NMR spectroscopy. High Resolution NMR was used to collect 
1
H 
NMR, 
19
F NMR and COSY data. Shown below in Figures 4.10-4.13 is the 
1
H NMR, 
19
F 
NMR, LCMS and COSY spectra for compound 125. 
1
H NMR has been labeled for 
structural characterization. 
19
F NMR shows a single peak because of the fluorine (F) 
group attached on ciprofloxacin. LCMS shows the mol. wt base peak of 640.19 
confirming the compound 125. 
Similar data was collected for analogs 126-130 (appendix). Each gave corresponding 
proof of structure in particular, the crucial presence of equimolar amount of the N-acyl 
ciprofloxacin and N-thiolated β-lactam, and the requisite O-acylated linkage to the β-
lactam. After all the purification steps, there was unfortunately barely a small amount of 
purified compound 130 left to do a 
1
H NMR. Thus, a cold probe 500 MHz NMR 
spectrometer was used to collect the spectral information. The compound still contained a 
small amount of impurities but shows characteristic NMR signals of the acylation. 
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Specifically, the C3 proton of the β-lactam resonates at ~6.7δ versus ~5.2δ of the starting 
hydroxylactam. 
 
Figure 4.10. 
1
H NMR of Compound 125.  
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Figure 4.11. 
19
F NMR showing the vinyl fluorine atom in the N-acyl ciprofloxacin- 
N-thiolated β-lactam hybrid 125. 
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Figure 4.12. LCMS showing peak at 641.2 (Mol. wt of compound 125 is 640.19). 
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Figure 4.13. COSY NMR data for compound 125 on 600 MHz NMR. 
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Figure 4.14 below shows the N-acyl ciprofloxacin-N-thiolated β-lactam analogs 
synthesized for this study. 
 
Figure 4.14. N-acyl ciprofloxacin-N-thiolated β-lactam analogs. 
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4.5.4 Attempted synthesis of Penicillin G-N-thiolated β-lactams Dual-action drugs. 
Through a parallel procedure, an attempt was made to synthesize penicillin G-N-thiolated 
β-lactams. Figure 4.14 below shows the reaction of N-acrylated penicillin G with N-
thiolated-β-lactams. Unfortunately, the coupling was not successful. 
 
Figure 4.15. Attempted coupling of acrylated PenG with N-thiolated-β-lactams. 
 
4.6. Biological testing. 
Six analogs of the ciprofloxacin-N thiolated β-lactam were successfully synthesized. All 
these compounds were then tested against ESKAPE pathogens for bio-activity by 
Whittney Burda in Dr. Lindsey Shaw’s laboratory (USF Department of Cell Biology, 
Microbiology and Molecular Biology). The ESKAPE pathogens are a collection of six 
deadly superbugs, Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, 
Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species. Each 
compound was tested in triplicates and it was observed that the compounds do not show 
any activity when tested for growth at all concentrations against E. faecium, K. 
pneumoniae, A. baumannii, P. aeruginosa, and E. cloacae.  Compounds 125 and 130 
displayed very good bioactivity against S. aureus, with MIC values of 1 µg/ml and 10 
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µg/ml, respectively. Each table below depicts whether growth was observed for each of 
the bacterial species. G denotes growth and X denotes no growth in the tables. 
G  Growth 
X No Growth 
 
Table 4.1.  Activity against Enterococcus faecium. 
 lactam 
1 
μg/ml 
2 
μg/ml 
3 
μg/ml 
4 
μg/ml 
5 
μg/ml 
6 
μg/ml 
7 
μg/ml 
8 
μg/ml 
9 
μg/ml 
10 
μg/ml 
25 
μg/ml 
125 G G G G G G G G G G G 
126 G G G G G G G G G G G 
127 G G G G G G G G G G G 
128 G G G G G G G G G G G 
129 G G G G G G G G G G G 
130 G G G G G G G G G G G 
 
Table 4.2. Activity against Staphylococcus aureus. 
 lactam 
1 
μg/ml 
2 
μg/ml 
3 
μg/ml 
4 
μg/ml 
5 
μg/ml 
6 
μg/ml 
7 
μg/ml 
8 
μg/ml 
9 
μg/ml 
10 
μg/ml 
25 
μg/ml 
125 
X X X X X X X X X X X 
126 
G G G G G G G G G G G 
127 
G G G G G G G G G G G 
128 
G G G G G G G G G G G 
129 
G G G G G G G G G G G 
130 
G G G G G G G G G X X 
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Table 4.3. Activity against Klebesiella pneumonia. 
 lactam 
1 
μg/ml 
2 
μg/ml 
3 
μg/ml 
4 
μg/ml 
5 
μg/ml 
6 
μg/ml 
7 
μg/ml 
8 
μg/ml 
9 
μg/ml 
10 
μg/ml 
25 
μg/ml 
125 G G G G G G G G G G G 
126 G G G G G G G G G G G 
127 G G G G G G G G G G G 
128 G G G G G G G G G G G 
129 G G G G G G G G G G G 
130 G G G G G G G G G G G 
 
Table 4.4. Activity against Acinetobacter baumannii. 
 lactam 
1 μg/ml 2 μg/ml 3 μg/ml 4 μg/ml 5 μg/ml 6 μg/ml 7 μg/ml 8 μg/ml 9 μg/ml 10 μg/ml 25 μg/ml 
125 
G G G G G G G G G G G 
126 
G G G G G G G G G G G 
127 
G G G G G G G G G G G 
128 
G G G G G G G G G G G 
129 
G G G G G G G G G G G 
130 
G G G G G G G G G G G 
  
Table 4.5. Activity against Pseudomonas aeruginosa. 
 lactam 
1 
μg/ml 
2 
μg/ml 
3 
μg/ml 
4 
μg/ml 
5 
μg/ml 
6 
μg/ml 
7 
μg/ml 
8 
μg/ml 
9 
μg/ml 
10 
μg/ml 
25 
μg/ml 
125 
G G G G G G G G G G G 
126 
G G G G G G G G G G G 
127 
G G G G G G G G G G G 
128 
G G G G G G G G G G G 
129 
G G G G G G G G G G G 
130 
G G G G G G G G G G G 
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4.7. Conclusion. 
Synthesis of dual drugs for the antibacterial purposes is a huge arena of research and for 
the first time this was done with the N-thiolated β-lactams. Though both N-acyl 
ciprofloxacins and N-thiolated β-lactams have been extensively studied by previous 
graduate students in the Turos laboratory, the attempt to combine them via a cleavable 
covalent bond was never done. This chapter has elaborated on the synthesis of six such 
analogs. Lactam 125 complete growth inhibition at 1 μg/ml against MRSA. Further 
testing is needed to determine the in vitro MIC value. 
Bacterial resistance is continuously increasing and it is a huge concern as the number of 
new drugs that has been cleared by FDA in the last 20 years has fallen drastically.
21, 22
 
Since a single drug is not always sufficient to control diseases or stop resistance on its 
own, it is an excellent idea to use a combination of drugs with different 
pharmacotherapeutic profiles. 
Apart from N-acyl ciprofloxacin-N-thiolated β-lactams shown in this chapter, many new 
and different drug combinations may be tried and tested. Coupling of aztreonam-N-
thiolated β-lactams, penicillin-N-thiolated β-lactams, Moxifloxacin-N-thiolated β-lactams 
etc should be interesting to look, particularly in regards to the resistance in drug-resistant 
mutant strains. Cleavable linkers play a very important role in chemical biology and are 
crucial for synthesis, and thus the study of the cleavability of these dual drugs in buffer 
and in the presence of esterases, acid or base should be carried out. In the ﬁeld of drug 
delivery, some of the important cleavable linkers that might be considered are 
enzymatically degradable linkers, nucleophile/base sensitive linkers, electrophile/acid 
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sensitive linkers, reduction sensitive linkers or photocleavable linkers. Some of the 
cleavable linkers that might be interesting to look at would be: dialkyl and 
diaryldialkoxysilane, orthoester, acetal, aconityl, hydrazone, β-thiopropionate, 
phosphoramidate, imine, trityl, vinyl ether, and polyketal linkers.
23
 Some examples are 
shown below. 
 
Figure 4.16. Examples of acidic sensitive linkers. 
 
This appears to be a suitable topic for further study in development of approaches to deal 
with deadly bacterial infections. It would be interesting to synthesize and test other dual-
action drugs as mentioned earlier or tri-action drugs or multi-action drugs. These kinds of 
combination drugs hold huge potential and working cohesively with the biologist would 
help to make drugs which can combat these superbugs and particularly towards drug-
resistance. 
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APPENDIX A:
 1
H NMR, 
19
F NMR, COSY LCMS DATA 
 
 
 
 
 
Figure A.1.1: 
1
H NMR (250 MHz, CDCl3) (IA) 
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APPENDIX A (continued) 
 
 
 
Figure A.1.2: 
1
H NMR (250 MHz, CDCl3) (IIA) 
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APPENDIX A (continued) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A.1.3: 1H NMR (250 MHz, CDCl3) (IIIA) 
Impurity
Impurity 
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APPENDIX A (continued) 
 
 
Figure A.1.4: 
1
H NMR (250 MHz, CDCl3) (88) 
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APPENDIX A (continued) 
 
 
Figure A.1.5: 
1
H NMR (250 MHz, CDCl3) (60*) 
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APPENDIX A (continued) 
 
 
 
 
Figure A.1.6: 
1
H NMR (250 MHz, CDCl3) (60a*) 
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APPENDIX A (continued) 
 
 
 
Figure A.1.7: 
1
H NMR (250 MHz, CDCl3) (E) 
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APPENDIX A (continued) 
 
 
Figure A.1.8: 
1
H NMR (250 MHz, CDCl3) (E; R’= sec-butyl) 
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APPENDIX A (continued) 
 
Figure A.1.9: 
1
H NMR (250 MHz, CDCl3) (107) 
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APPENDIX A (continued) 
 
 
 
Figure A.1.10: 
1
H NMR (250 MHz, CDCl3) (108) 
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APPENDIX A (continued) 
 
 
 
Figure A.1.11: 
1
H NMR (250 MHz, CDCl3) (109) 
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APPENDIX A (continued) 
 
 
 
Figure A.1.12: 
1
H NMR (250 MHz, CDCl3) (110) 
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Figure A.1.13: 
1
H NMR (250 MHz, CDCl3) (111) 
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Figure A.1.14: 
1
H NMR (250 MHz, CDCl3) (112) 
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Figure A.1.15: 
1
H NMR (400 MHz, CDCl3) (113) 
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Figure A.1.16: 
1
H NMR (250 MHz, CDCl3) (114) 
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Figure A.1.17: 
1
H NMR (250 MHz, CDCl3) (115) 
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Figure A.1.18: 
1
H NMR (250 MHz, CDCl3) (116) 
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Figure A.1.19: 
1
H NMR (250 MHz, CDCl3) (117) 
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Figure A.1.20: 
1
H NMR (250 MHz, CDCl3) (118) 
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Figure A.1.21: 
1
H NMR (250 MHz, CDCl3) (119) 
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Figure A.1.22: 
1
H NMR (250 MHz, CDCl3) (120) 
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Figure A.1.23. 
1
H NMR (250 MHz, CDCl3) (121) 
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Figure A.1.24: 
1
H NMR (600 MHz, CDCl3) (125)  
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Figure A.1.25: 
1
H NMR (500 MHz, CDCl3) (126)  
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Figure A.1.26: 
1
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Figure A.1.27: 
1
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Figure A.1.28: 
1
H NMR (400 MHz, CDCl3) (129)  
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Figure A.1.29: 
1
H NMR (500 MHz, CDCl3) (130)  
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Figure A.1.30: LCMS (125)  
   
197 
 
APPENDIX A (continued) 
 
 
 
Figure A.1.31: LCMS (126)  
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Figure A.1.32: LCMS (127)  
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Figure A.1.33: LCMS (128)  
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Figure A.1.34: LCMS (129)  
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Figure A.1.35: LCMS (130)  
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Figure A.1.36: COSY (600 MHz, CDCl3) (125)  
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Figure A.1.37: 
19
F NMR (400 MHz, CDCl3) (126)  
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